PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16024620-5	2005	Enzymatic products of stromal cell L-PGDS included high levels of PGD2 and 15-deoxy-delta(12,14)-PGD2 but low levels of 15-deoxy-delta(12,14)-prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	142-158	prostaglandin D2 synthase	Homo sapiens	35-41
15911346-0	2005	Inhibition of sequestosome 1/p62 up-regulation prevents aggregation of ubiquitinated proteins induced by prostaglandin J2 without reducing its neurotoxicity.	9-deoxy-delta-9-prostaglandin D2	105-121	sequestosome 1	Homo sapiens	14-28
15713689-0	2005	Stimulation of NGF expression and secretion in 3T3-L1 adipocytes by prostaglandins PGD2, PGJ2, and Delta12-PGJ2.	9-deoxy-delta-9-prostaglandin D2	89-93	nerve growth factor	Mus musculus	15-18
15911346-0	2005	Inhibition of sequestosome 1/p62 up-regulation prevents aggregation of ubiquitinated proteins induced by prostaglandin J2 without reducing its neurotoxicity.	9-deoxy-delta-9-prostaglandin D2	105-121	sequestosome 1	Homo sapiens	29-32
15911346-2	2005	We report that prostaglandin J2 (PGJ2), an endogenous product of inflammation, up-regulates sequestosome 1/p62 in a time- and dose-dependent manner in human neuroblastoma SK-N-SH cells.	9-deoxy-delta-9-prostaglandin D2	15-31	sequestosome 1	Homo sapiens	92-106
15911346-2	2005	We report that prostaglandin J2 (PGJ2), an endogenous product of inflammation, up-regulates sequestosome 1/p62 in a time- and dose-dependent manner in human neuroblastoma SK-N-SH cells.	9-deoxy-delta-9-prostaglandin D2	15-31	sequestosome 1	Homo sapiens	107-110
15911346-2	2005	We report that prostaglandin J2 (PGJ2), an endogenous product of inflammation, up-regulates sequestosome 1/p62 in a time- and dose-dependent manner in human neuroblastoma SK-N-SH cells.	9-deoxy-delta-9-prostaglandin D2	33-37	sequestosome 1	Homo sapiens	92-106
15911346-2	2005	We report that prostaglandin J2 (PGJ2), an endogenous product of inflammation, up-regulates sequestosome 1/p62 in a time- and dose-dependent manner in human neuroblastoma SK-N-SH cells.	9-deoxy-delta-9-prostaglandin D2	33-37	sequestosome 1	Homo sapiens	107-110
15911346-4	2005	Herein, we show that sequestosome 1/p62 is co-localized with ubiquitinated proteins and the ubiquitin hydrolase UCH-L1 in cytoplasmic aggregates induced by PGJ2.	9-deoxy-delta-9-prostaglandin D2	156-160	sequestosome 1	Homo sapiens	21-35
15911346-4	2005	Herein, we show that sequestosome 1/p62 is co-localized with ubiquitinated proteins and the ubiquitin hydrolase UCH-L1 in cytoplasmic aggregates induced by PGJ2.	9-deoxy-delta-9-prostaglandin D2	156-160	sequestosome 1	Homo sapiens	36-39
15911346-4	2005	Herein, we show that sequestosome 1/p62 is co-localized with ubiquitinated proteins and the ubiquitin hydrolase UCH-L1 in cytoplasmic aggregates induced by PGJ2.	9-deoxy-delta-9-prostaglandin D2	156-160	ubiquitin C-terminal hydrolase L1	Homo sapiens	112-118
15819389-1	2005	15-Deoxy-delta(12, 14)-prostaglandin J2 (15d-PG J2) is a regulator of a nuclear transcriptional factor, peroxisome proliferator-activated receptor (PPAR)-gamma.	9-deoxy-delta-9-prostaglandin D2	21-39	peroxisome proliferator activated receptor gamma	Mus musculus	104-159
15590897-1	2005	Recently, we demonstrated that the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands, either 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) or ciglitazone, increased endothelial nitric oxide (.NO) release without altering endothelial nitric oxide synthase (eNOS) expression (4).	9-deoxy-delta-9-prostaglandin D2	155-159	peroxisome proliferator activated receptor gamma	Homo sapiens	35-83
15822171-4	2005	Among their substrates, GSTs conjugate the signaling molecules 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2) and 4-hydroxynonenal with glutathione, and consequently they antagonize expression of genes trans-activated by the peroxisome proliferator-activated receptor gamma (PPARgamma) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2).	9-deoxy-delta-9-prostaglandin D2	85-101	glutathione S-transferase, alpha 4	Mus musculus	24-28
15822171-4	2005	Among their substrates, GSTs conjugate the signaling molecules 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2) and 4-hydroxynonenal with glutathione, and consequently they antagonize expression of genes trans-activated by the peroxisome proliferator-activated receptor gamma (PPARgamma) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2).	9-deoxy-delta-9-prostaglandin D2	85-101	NFE2 like bZIP transcription factor 2	Homo sapiens	342-346
15994020-7	2005	The natural peroxisome proliferator-activated receptor-gamma ligand, 15-deoxy-delta(12,14) prostaglandin J2, and the cyclic AMP analog, bromo cyclic AMP, significantly attenuated the strong induction of peroxisome proliferator-activated receptor-gamma and inducible nitric oxide synthase, while they partially reversed the inhibitory effect of OTA on glial fibrillary acidic protein.	9-deoxy-delta-9-prostaglandin D2	91-107	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	12-60
15797264-5	2005	Hypoxia-induced release of PGD2/PGJ2 was COX-1 dependent and did not involve COX-2.	9-deoxy-delta-9-prostaglandin D2	32-36	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	41-46
15994020-7	2005	The natural peroxisome proliferator-activated receptor-gamma ligand, 15-deoxy-delta(12,14) prostaglandin J2, and the cyclic AMP analog, bromo cyclic AMP, significantly attenuated the strong induction of peroxisome proliferator-activated receptor-gamma and inducible nitric oxide synthase, while they partially reversed the inhibitory effect of OTA on glial fibrillary acidic protein.	9-deoxy-delta-9-prostaglandin D2	91-107	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	203-251
15994020-7	2005	The natural peroxisome proliferator-activated receptor-gamma ligand, 15-deoxy-delta(12,14) prostaglandin J2, and the cyclic AMP analog, bromo cyclic AMP, significantly attenuated the strong induction of peroxisome proliferator-activated receptor-gamma and inducible nitric oxide synthase, while they partially reversed the inhibitory effect of OTA on glial fibrillary acidic protein.	9-deoxy-delta-9-prostaglandin D2	91-107	nitric oxide synthase 2	Rattus norvegicus	256-287
15523637-5	2004	PGJ2 derivatives, such as 15d-PGJ2, are known activators of PPARgamma, a nuclear receptor that activates gene expression.	9-deoxy-delta-9-prostaglandin D2	0-4	peroxisome proliferator activated receptor gamma	Homo sapiens	60-69
15523637-0	2004	Neurotoxic prostaglandin J2 enhances cyclooxygenase-2 expression in neuronal cells through the p38MAPK pathway: a death wish?	9-deoxy-delta-9-prostaglandin D2	11-27	prostaglandin-endoperoxide synthase 2	Homo sapiens	37-53
15523637-6	2004	However, the selective PPARgamma agonist ciglitazone failed to up-regulate COX-2, indicating that the PGJ2 effect on COX-2 is PPARgamma independent.	9-deoxy-delta-9-prostaglandin D2	102-106	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	117-122
15523637-3	2004	Here we demonstrate that PGJ2 enhances COX-2 gene expression without elevating COX-1 levels in neuronal cells.	9-deoxy-delta-9-prostaglandin D2	25-29	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	39-44
15523637-4	2004	PGJ2 also increased PGE2 production, establishing that the de novo synthesized COX-2 is enzymatically active.	9-deoxy-delta-9-prostaglandin D2	0-4	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	79-84
15523637-6	2004	However, the selective PPARgamma agonist ciglitazone failed to up-regulate COX-2, indicating that the PGJ2 effect on COX-2 is PPARgamma independent.	9-deoxy-delta-9-prostaglandin D2	102-106	peroxisome proliferator activated receptor gamma	Homo sapiens	126-135
15523637-7	2004	Furthermore, PGJ2 stabilized IkappaBalpha levels, indicating that NFkappaB is not active under these conditions.	9-deoxy-delta-9-prostaglandin D2	13-17	NFKB inhibitor alpha	Homo sapiens	29-41
15523637-8	2004	The blocking of neuronal NFkappaB activity by PGJ2 may be an important contributor to its neurotoxicity, insofar as NFkappaB transactivation seems to be required for neuronal survival in the CNS.	9-deoxy-delta-9-prostaglandin D2	46-50	nuclear factor kappa B subunit 1	Homo sapiens	25-33
15523637-10	2004	Notably, IL1 mRNA levels in the neuronal cells were increased by PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	65-69	interleukin 1 alpha	Homo sapiens	9-12
15523637-11	2004	The proinflammatory cytokine may mediate COX-2 up-regulation by PGJ2 through p38MAPK and not JNK activation, in that only an inhibitor of the former prevented the COX-2 increase.	9-deoxy-delta-9-prostaglandin D2	64-68	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	41-46
15662752-16	2004	15-d-PGJ2 metabolite binds PPAR-gamma promotes adipocyte differentiation.	9-deoxy-delta-9-prostaglandin D2	5-9	peroxisome proliferator activated receptor gamma	Homo sapiens	27-37
15523637-11	2004	The proinflammatory cytokine may mediate COX-2 up-regulation by PGJ2 through p38MAPK and not JNK activation, in that only an inhibitor of the former prevented the COX-2 increase.	9-deoxy-delta-9-prostaglandin D2	64-68	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	163-168
15523637-13	2004	Collectively, our findings suggest that proinflammatory conditions that lead to COX-2 up-regulation and the concomitant production of PGJ2 initiate a mechanism of self-destruction through an autotoxic loop between PGJ2 and COX-2 that may exacerbate neurodegeneration beyond a point of no return.	9-deoxy-delta-9-prostaglandin D2	134-138	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	223-228
15523637-13	2004	Collectively, our findings suggest that proinflammatory conditions that lead to COX-2 up-regulation and the concomitant production of PGJ2 initiate a mechanism of self-destruction through an autotoxic loop between PGJ2 and COX-2 that may exacerbate neurodegeneration beyond a point of no return.	9-deoxy-delta-9-prostaglandin D2	214-218	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	80-85
15545828-0	2004	The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyDelta12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock.	9-deoxy-delta-9-prostaglandin D2	79-95	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	4-52
15258247-0	2004	Influence of peroxisome proliferator-activated receptor gamma activation by its endogenous ligand 15-deoxy Delta12,14 prostaglandin J2 on nitric oxide production in term placental tissues from diabetic women.	9-deoxy-delta-9-prostaglandin D2	118-134	peroxisome proliferator activated receptor gamma	Homo sapiens	13-61
15557816-6	2004	One of the earliest events observed in Delta(12)-PGJ(2)-induced apoptotic events was dissipation of Deltapsi(m), the process known to be inhibited by bcl-2.	9-deoxy-delta-9-prostaglandin D2	49-55	BCL2 apoptosis regulator	Homo sapiens	150-155
15470065-6	2004	The 15d-PGJ2 inhibited the recruitment of p300 by NF-kappaB (p65) and down-regulated the p300-mediated induction of iNOS and NF-kappaB luciferase reporter activity.	9-deoxy-delta-9-prostaglandin D2	7-12	synaptotagmin 1	Rattus norvegicus	61-64
15470065-6	2004	The 15d-PGJ2 inhibited the recruitment of p300 by NF-kappaB (p65) and down-regulated the p300-mediated induction of iNOS and NF-kappaB luciferase reporter activity.	9-deoxy-delta-9-prostaglandin D2	7-12	nitric oxide synthase 2	Rattus norvegicus	116-120
15251113-3	2004	In this study, the effects of PPARgamma (15d PGJ2 and ciglitizone) ligands on proliferation, cytokine production and apoptosis of Jurkat and Raji cells (human T and B lymphocytes, respectively) were examined.	9-deoxy-delta-9-prostaglandin D2	45-49	peroxisome proliferator activated receptor gamma	Homo sapiens	30-39
15251113-5	2004	In addition, 15d PGJ2 inhibited cytokine production (IL-2 in Jurkat cells and IL-10 in Raji cells).	9-deoxy-delta-9-prostaglandin D2	17-21	interleukin 2	Homo sapiens	53-57
15251113-5	2004	In addition, 15d PGJ2 inhibited cytokine production (IL-2 in Jurkat cells and IL-10 in Raji cells).	9-deoxy-delta-9-prostaglandin D2	17-21	interleukin 10	Homo sapiens	78-83
15150131-10	2004	PGJ2 + RA increased the binding of the PPARgamma - RXR heterodimer to the putative PPAR-response elements (PPREs) in the GSTA2 promoter.	9-deoxy-delta-9-prostaglandin D2	0-4	peroxisome proliferator activated receptor gamma	Homo sapiens	39-48
15265671-0	2004	15-deoxy-delta (12,14)-PGJ2 inhibits astrocyte IL-1 signaling: inhibition of NF-kappaB and MAP kinase pathways and suppression of cytokine and chemokine expression.	9-deoxy-delta-9-prostaglandin D2	21-27	interleukin 1 alpha	Homo sapiens	47-51
15265671-0	2004	15-deoxy-delta (12,14)-PGJ2 inhibits astrocyte IL-1 signaling: inhibition of NF-kappaB and MAP kinase pathways and suppression of cytokine and chemokine expression.	9-deoxy-delta-9-prostaglandin D2	21-27	nuclear factor kappa B subunit 1	Homo sapiens	77-86
15304743-4	2004	SC-560, a specific COX-1 inhibitor, suppressed adipogenesis dose dependently, suggesting a role of constitutive COX-1 in the endogenous synthesis of PGs, including PGJ2 derivatives formed by mature adipocytes with the ability to promote adipogenesis.	9-deoxy-delta-9-prostaglandin D2	164-168	cytochrome c oxidase I, mitochondrial	Mus musculus	112-117
15304745-5	2004	Moreover, we confirmed the formation of PGD2 from arachidonic acid by the mature adipocytes, suggesting conversion into PGJ2 derivatives.	9-deoxy-delta-9-prostaglandin D2	120-124	prostaglandin D2 synthase (brain)	Mus musculus	40-44
15150131-10	2004	PGJ2 + RA increased the binding of the PPARgamma - RXR heterodimer to the putative PPAR-response elements (PPREs) in the GSTA2 promoter.	9-deoxy-delta-9-prostaglandin D2	0-4	retinoid X receptor alpha	Homo sapiens	51-54
15150131-10	2004	PGJ2 + RA increased the binding of the PPARgamma - RXR heterodimer to the putative PPAR-response elements (PPREs) in the GSTA2 promoter.	9-deoxy-delta-9-prostaglandin D2	0-4	peroxisome proliferator activated receptor alpha	Homo sapiens	39-43
15150131-10	2004	PGJ2 + RA increased the binding of the PPARgamma - RXR heterodimer to the putative PPAR-response elements (PPREs) in the GSTA2 promoter.	9-deoxy-delta-9-prostaglandin D2	0-4	glutathione S-transferase alpha 2	Homo sapiens	121-126
15150131-12	2004	Transactivation of PPREM by the PPARgamma - RXR heterodimer was verified by the effective GSTA2 induction in the cells treated with PGJ2 + RA after transfecting them with the plasmids encoding PPARgamma1 and RXRalpha.	9-deoxy-delta-9-prostaglandin D2	132-136	peroxisome proliferator activated receptor gamma	Homo sapiens	32-41
15150131-12	2004	Transactivation of PPREM by the PPARgamma - RXR heterodimer was verified by the effective GSTA2 induction in the cells treated with PGJ2 + RA after transfecting them with the plasmids encoding PPARgamma1 and RXRalpha.	9-deoxy-delta-9-prostaglandin D2	132-136	retinoid X receptor alpha	Homo sapiens	44-47
15150131-12	2004	Transactivation of PPREM by the PPARgamma - RXR heterodimer was verified by the effective GSTA2 induction in the cells treated with PGJ2 + RA after transfecting them with the plasmids encoding PPARgamma1 and RXRalpha.	9-deoxy-delta-9-prostaglandin D2	132-136	glutathione S-transferase alpha 2	Homo sapiens	90-95
15150131-12	2004	Transactivation of PPREM by the PPARgamma - RXR heterodimer was verified by the effective GSTA2 induction in the cells treated with PGJ2 + RA after transfecting them with the plasmids encoding PPARgamma1 and RXRalpha.	9-deoxy-delta-9-prostaglandin D2	132-136	retinoid X receptor alpha	Homo sapiens	208-216
15047143-7	2004	Prostaglandin J2 and protein C kinase inhibitors significantly inhibited [3H]thymidine incorporation in RMC incubated with VEGF, which was inhibited by TZD.	9-deoxy-delta-9-prostaglandin D2	0-16	vascular endothelial growth factor A	Rattus norvegicus	123-127
15090969-11	2004	The specific PPAR-gamma antagonist GW9662 reduced the protective effects afforded by 15 d-PGJ2.	9-deoxy-delta-9-prostaglandin D2	89-94	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	13-23
14979731-8	2004	However, expression of any of the three GSTs significantly inhibited 15-d-PGJ(2)-dependent transactivation of a PPAR gamma-responsive reporter gene.	9-deoxy-delta-9-prostaglandin D2	74-80	glutathione S-transferase mu 1	Homo sapiens	40-44
14979731-8	2004	However, expression of any of the three GSTs significantly inhibited 15-d-PGJ(2)-dependent transactivation of a PPAR gamma-responsive reporter gene.	9-deoxy-delta-9-prostaglandin D2	74-80	peroxisome proliferator activated receptor gamma	Homo sapiens	112-122
14600076-1	2004	Peroxisome proliferator-activated receptor (PPAR)gamma agonists, such as 15-deoxy-delta 12,14-prostaglandin J2 (PGJ2) and troglitazone, have been shown to elicit anti-inflammatory effects in pancreatic beta-cells that include inhibition of cytokine-stimulated inducible nitric oxide synthase (iNOS) gene expression and production of nitric oxide.	9-deoxy-delta-9-prostaglandin D2	112-116	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	44-48
14600076-1	2004	Peroxisome proliferator-activated receptor (PPAR)gamma agonists, such as 15-deoxy-delta 12,14-prostaglandin J2 (PGJ2) and troglitazone, have been shown to elicit anti-inflammatory effects in pancreatic beta-cells that include inhibition of cytokine-stimulated inducible nitric oxide synthase (iNOS) gene expression and production of nitric oxide.	9-deoxy-delta-9-prostaglandin D2	112-116	nitric oxide synthase 2	Rattus norvegicus	293-297
14600076-3	2004	The purpose of this study was to determine if PPARgamma activation participates in the anti-inflammatory actions of PGJ2 in beta-cells.	9-deoxy-delta-9-prostaglandin D2	116-120	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	46-55
14600076-4	2004	Pretreatment of RINm5F cells for 6 h with PGJ2 results in inhibition of IL-1-stimulated IkappaB degradation and IFN-gamma-stimulated STAT1 phosphorylation.	9-deoxy-delta-9-prostaglandin D2	42-46	interferon gamma	Rattus norvegicus	112-121
14600076-4	2004	Pretreatment of RINm5F cells for 6 h with PGJ2 results in inhibition of IL-1-stimulated IkappaB degradation and IFN-gamma-stimulated STAT1 phosphorylation.	9-deoxy-delta-9-prostaglandin D2	42-46	signal transducer and activator of transcription 1	Rattus norvegicus	133-138
14600076-6	2004	Although these agents fail to attenuate the inhibitory actions of PGJ2 on cytokine signaling, they do inhibit PGJ2-stimulated PPARgamma response element reporter activity.	9-deoxy-delta-9-prostaglandin D2	110-114	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	126-135
15090969-0	2004	Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin.	9-deoxy-delta-9-prostaglandin D2	106-122	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	8-56
15041706-8	2004	RESULTS: We showed that the PPARgamma ligands PGJ2 and ciglitazone inhibit the growth and induce the apoptosis of several human lung carcinoma cell lines, whereas the PPARalpha agonist WY14643 has little effect.	9-deoxy-delta-9-prostaglandin D2	46-50	peroxisome proliferator activated receptor gamma	Homo sapiens	28-37
15090969-14	2004	The mechanisms of the protective effect of this cyclopentenone prostaglandin are--at least in part--PPAR-gamma dependent, as the protection afforded by 15 d-PGJ2 was reduced by the PPAR-gamma antagonist GW9662.	9-deoxy-delta-9-prostaglandin D2	157-161	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	100-110
15090969-14	2004	The mechanisms of the protective effect of this cyclopentenone prostaglandin are--at least in part--PPAR-gamma dependent, as the protection afforded by 15 d-PGJ2 was reduced by the PPAR-gamma antagonist GW9662.	9-deoxy-delta-9-prostaglandin D2	157-161	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	181-191
15090969-15	2004	We propose that 15 d-PGJ2 or other ligands for PPAR-gamma may be useful in treating organ injury associated with endotoxic shock.	9-deoxy-delta-9-prostaglandin D2	21-25	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	47-57
15037811-0	2004	Possible involvement of p38 in mechanisms underlying acceleration of proliferation by 15-deoxy-Delta(12,14)-prostaglandin J2 and the precursors in leukemia cell line THP-1.	9-deoxy-delta-9-prostaglandin D2	108-124	mitogen-activated protein kinase 14	Homo sapiens	24-27
14624702-1	2003	BACKGROUND: As well as being inducible by haem, haemoxygenase -1 (HO-1) is also induced by interleukin-10 and an anti-inflammatory prostaglandin, 15d PGJ2, the carbon monoxide thus produced mediating the anti-inflammatory effects of these molecules.	9-deoxy-delta-9-prostaglandin D2	150-154	heme oxygenase 1	Homo sapiens	48-70
15037811-8	2004	FACScan analysis revealed that PGD2 at 5 microM, PGJ2 at 1 microM, DeltaPGJ2 at 1 microM and 15dPGJ2 at 5 microM all accelerated cell cycle progression in THP-1.	9-deoxy-delta-9-prostaglandin D2	49-53	GLI family zinc finger 2	Homo sapiens	155-160
15028947-3	2004	The purpose of this study was to investigate the role of MAPKs (ERK, JNK, and p38) in 15d-PGJ2-induced pancreatic cancer cell apoptosis.	9-deoxy-delta-9-prostaglandin D2	90-94	mitogen-activated protein kinase 1	Homo sapiens	64-67
15028947-3	2004	The purpose of this study was to investigate the role of MAPKs (ERK, JNK, and p38) in 15d-PGJ2-induced pancreatic cancer cell apoptosis.	9-deoxy-delta-9-prostaglandin D2	90-94	mitogen-activated protein kinase 14	Homo sapiens	78-81
15028947-8	2004	SB202190, an inhibitor of p38, prevented 15d-PGJ2-induced activation of caspase-8, -9, and -3 and significantly decreased apoptosis.	9-deoxy-delta-9-prostaglandin D2	45-49	mitogen-activated protein kinase 14	Homo sapiens	26-29
15028947-8	2004	SB202190, an inhibitor of p38, prevented 15d-PGJ2-induced activation of caspase-8, -9, and -3 and significantly decreased apoptosis.	9-deoxy-delta-9-prostaglandin D2	45-49	caspase 8	Homo sapiens	72-93
14751245-5	2004	We found that human non-small cell lung carcinoma cell lines (H1838 and H2106) express EP2 receptors, and that the inhibition of cell growth by PPARgamma ligands (GW1929, PGJ2, ciglitazone, troglitazone, and rosiglitazone [also known as BRL49653]) was associated with a significant decrease in EP2 mRNA and protein levels.	9-deoxy-delta-9-prostaglandin D2	171-175	prostaglandin E receptor 2	Homo sapiens	87-90
14962493-6	2004	Immunohistochemical analysis of p65 translocation and Western blot analysis of IkappaB-alpha degradation revealed that 15-deoxy-Delta(12,14)-prostaglandin J2 inhibited the activation of nuclear factor (NF)-kappaB in renal cells.	9-deoxy-delta-9-prostaglandin D2	141-157	synaptotagmin 1	Rattus norvegicus	32-35
14962493-6	2004	Immunohistochemical analysis of p65 translocation and Western blot analysis of IkappaB-alpha degradation revealed that 15-deoxy-Delta(12,14)-prostaglandin J2 inhibited the activation of nuclear factor (NF)-kappaB in renal cells.	9-deoxy-delta-9-prostaglandin D2	141-157	NFKB inhibitor alpha	Rattus norvegicus	79-92
14704122-3	2004	RESULTS: The 15d-PGJ2 induced apoptosis in ECV304 endothelial cells in a dose-dependent manner (the percentage of apoptosis was enhanced from 10.0 %+/-1.3 % to 32.8 %+/-1.6 %), which was accompanied by inhibition of NF-?B and AP-1 DNA binding activity, down-regulation of c-myc, upregulation of Gadd45 and p53, and activation of p38 kinase.	9-deoxy-delta-9-prostaglandin D2	17-21	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	272-277
14704122-3	2004	RESULTS: The 15d-PGJ2 induced apoptosis in ECV304 endothelial cells in a dose-dependent manner (the percentage of apoptosis was enhanced from 10.0 %+/-1.3 % to 32.8 %+/-1.6 %), which was accompanied by inhibition of NF-?B and AP-1 DNA binding activity, down-regulation of c-myc, upregulation of Gadd45 and p53, and activation of p38 kinase.	9-deoxy-delta-9-prostaglandin D2	17-21	tumor protein p53	Homo sapiens	306-309
14636064-3	2003	In the study presented here, we investigated the molecular mechanisms involved in the 15d-PGJ(2)-induced accumulation of p53.	9-deoxy-delta-9-prostaglandin D2	90-96	tumor protein p53	Homo sapiens	121-124
14573767-4	2003	15-Deoxy-Delta12,14 prostaglandin J2 (15d-PGJ2) and ciglitazone, two representative PPAR-gamma ligands, significantly inhibited IL-4 production in both antigen-stimulated primary CD4+ T cells and the phorbol 12-myristate 13-acetate (PMA)/ionomycin-activated EL-4 T cell line.	9-deoxy-delta-9-prostaglandin D2	20-36	interleukin 4	Mus musculus	128-132
14512786-6	2003	Treatment of cells transfected with the luciferase gene ligated to PPAR response element constructed promoter showed that ciglitazone and prostaglandin J2 (PGJ2), selective ligands for PPARgamma, increased the luciferase activity, proving the induction of the PPARgamma reporter gene.	9-deoxy-delta-9-prostaglandin D2	138-154	peroxisome proliferator activated receptor alpha	Homo sapiens	67-71
14512786-6	2003	Treatment of cells transfected with the luciferase gene ligated to PPAR response element constructed promoter showed that ciglitazone and prostaglandin J2 (PGJ2), selective ligands for PPARgamma, increased the luciferase activity, proving the induction of the PPARgamma reporter gene.	9-deoxy-delta-9-prostaglandin D2	138-154	peroxisome proliferator activated receptor gamma	Homo sapiens	185-194
14512786-6	2003	Treatment of cells transfected with the luciferase gene ligated to PPAR response element constructed promoter showed that ciglitazone and prostaglandin J2 (PGJ2), selective ligands for PPARgamma, increased the luciferase activity, proving the induction of the PPARgamma reporter gene.	9-deoxy-delta-9-prostaglandin D2	138-154	peroxisome proliferator activated receptor gamma	Homo sapiens	260-269
14512786-6	2003	Treatment of cells transfected with the luciferase gene ligated to PPAR response element constructed promoter showed that ciglitazone and prostaglandin J2 (PGJ2), selective ligands for PPARgamma, increased the luciferase activity, proving the induction of the PPARgamma reporter gene.	9-deoxy-delta-9-prostaglandin D2	156-160	peroxisome proliferator activated receptor alpha	Homo sapiens	67-71
14512786-6	2003	Treatment of cells transfected with the luciferase gene ligated to PPAR response element constructed promoter showed that ciglitazone and prostaglandin J2 (PGJ2), selective ligands for PPARgamma, increased the luciferase activity, proving the induction of the PPARgamma reporter gene.	9-deoxy-delta-9-prostaglandin D2	156-160	peroxisome proliferator activated receptor gamma	Homo sapiens	185-194
14512786-6	2003	Treatment of cells transfected with the luciferase gene ligated to PPAR response element constructed promoter showed that ciglitazone and prostaglandin J2 (PGJ2), selective ligands for PPARgamma, increased the luciferase activity, proving the induction of the PPARgamma reporter gene.	9-deoxy-delta-9-prostaglandin D2	156-160	peroxisome proliferator activated receptor gamma	Homo sapiens	260-269
14592554-3	2003	This is most pronounced in the case of 15-deoxy PGJ2, a cyclopentanone derivative of PGJ2 as a ligand for PPARgamma.	9-deoxy-delta-9-prostaglandin D2	48-52	peroxisome proliferator activated receptor gamma	Mus musculus	106-115
12878983-4	2003	Our data indicate that the PPAR-gamma natural ligand 15d-PGJ2 dose-dependently inhibits expression of alkaline phosphatase and mineral deposition by primary stromal cells and by cell lines such as ST2 and MC3T3-E1.	9-deoxy-delta-9-prostaglandin D2	57-61	peroxisome proliferator activated receptor gamma	Homo sapiens	27-37
12898507-5	2003	The peroxisome-proliferator-activated receptor gamma (PPARgamma) agonists, rosiglitazone (ros), and 15-deoxy-Delta-(12,14)- prostaglandin J(2) (PGJ2) have been demonstrated to block TNF-alpha-induced lipolysis.	9-deoxy-delta-9-prostaglandin D2	144-148	peroxisome proliferator activated receptor gamma	Homo sapiens	4-52
12672447-5	2003	Products of cyclooxygenase 2, such as prostaglandin J2, can, in turn, increase the levels of ubiquitinated proteins and also cause cyclooxygenase 2 up-regulation, creating a "self-destructive" feedback mechanism.	9-deoxy-delta-9-prostaglandin D2	38-54	prostaglandin-endoperoxide synthase 2	Homo sapiens	12-28
12642589-2	2003	Here we show that at submicromolar concentrations (0.1-0.5 microM) 15d-PGJ2 retains the ability to suppress the production of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide (NO) in lipopolysaccharide (LPS)-activated murine J774 macrophages under the conditions of a prolonged incubation (>12 h).	9-deoxy-delta-9-prostaglandin D2	70-75	tumor necrosis factor	Mus musculus	126-153
12642589-2	2003	Here we show that at submicromolar concentrations (0.1-0.5 microM) 15d-PGJ2 retains the ability to suppress the production of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide (NO) in lipopolysaccharide (LPS)-activated murine J774 macrophages under the conditions of a prolonged incubation (>12 h).	9-deoxy-delta-9-prostaglandin D2	70-75	tumor necrosis factor	Mus musculus	155-164
12731885-0	2003	Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells.	9-deoxy-delta-9-prostaglandin D2	152-168	ATP binding cassette subfamily C member 1	Homo sapiens	0-36
12731885-0	2003	Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells.	9-deoxy-delta-9-prostaglandin D2	152-168	ATP binding cassette subfamily C member 3	Homo sapiens	41-45
12517740-3	2003	We show that PGJ(2) inhibits interferon (IFN)-gamma-stimulated phosphorylation and DNA-binding activity of STAT1.	9-deoxy-delta-9-prostaglandin D2	13-19	interferon gamma	Homo sapiens	29-51
12517740-3	2003	We show that PGJ(2) inhibits interferon (IFN)-gamma-stimulated phosphorylation and DNA-binding activity of STAT1.	9-deoxy-delta-9-prostaglandin D2	13-19	signal transducer and activator of transcription 1	Homo sapiens	107-112
12517740-5	2003	In previous studies, we have correlated the inhibitory actions of PGJ(2) on inducible nitric oxide synthase (iNOS) expression and NF-kappaB activation in response to IL-1 with the increased expression of HSP70.	9-deoxy-delta-9-prostaglandin D2	66-72	nitric oxide synthase 2	Homo sapiens	76-107
12517740-5	2003	In previous studies, we have correlated the inhibitory actions of PGJ(2) on inducible nitric oxide synthase (iNOS) expression and NF-kappaB activation in response to IL-1 with the increased expression of HSP70.	9-deoxy-delta-9-prostaglandin D2	66-72	nitric oxide synthase 2	Homo sapiens	109-113
12517740-5	2003	In previous studies, we have correlated the inhibitory actions of PGJ(2) on inducible nitric oxide synthase (iNOS) expression and NF-kappaB activation in response to IL-1 with the increased expression of HSP70.	9-deoxy-delta-9-prostaglandin D2	66-72	heat shock protein family A (Hsp70) member 4	Homo sapiens	204-209
12517740-7	2003	Last, we show that the inhibitory actions of a short 6-h pulse with PGJ(2) on IL-1 plus IFN-gamma-stimulated iNOS expression and NO production by beta-cells are persistent for extended periods (< or =48 h).	9-deoxy-delta-9-prostaglandin D2	68-74	interferon gamma	Homo sapiens	88-97
12517740-7	2003	Last, we show that the inhibitory actions of a short 6-h pulse with PGJ(2) on IL-1 plus IFN-gamma-stimulated iNOS expression and NO production by beta-cells are persistent for extended periods (< or =48 h).	9-deoxy-delta-9-prostaglandin D2	68-74	nitric oxide synthase 2	Homo sapiens	109-113
12672447-5	2003	Products of cyclooxygenase 2, such as prostaglandin J2, can, in turn, increase the levels of ubiquitinated proteins and also cause cyclooxygenase 2 up-regulation, creating a "self-destructive" feedback mechanism.	9-deoxy-delta-9-prostaglandin D2	38-54	prostaglandin-endoperoxide synthase 2	Homo sapiens	131-147
12615709-1	2003	Treatment of MCF-7 cells with the peroxisome proliferator-activated receptor (PPAR) gamma agonists ciglitazone or 15-deoxy-Delta 12,14-prostaglandin J2 resulted in a concentration- and time-dependent decrease of cyclin D1 and estrogen receptor (ER) alpha proteins, and this was accompanied by decreased cell proliferation and G(1)-G(0)-->S-phase progression.	9-deoxy-delta-9-prostaglandin D2	134-151	peroxisome proliferator activated receptor alpha	Homo sapiens	34-76
12615709-1	2003	Treatment of MCF-7 cells with the peroxisome proliferator-activated receptor (PPAR) gamma agonists ciglitazone or 15-deoxy-Delta 12,14-prostaglandin J2 resulted in a concentration- and time-dependent decrease of cyclin D1 and estrogen receptor (ER) alpha proteins, and this was accompanied by decreased cell proliferation and G(1)-G(0)-->S-phase progression.	9-deoxy-delta-9-prostaglandin D2	134-151	peroxisome proliferator activated receptor alpha	Homo sapiens	78-82
12615709-1	2003	Treatment of MCF-7 cells with the peroxisome proliferator-activated receptor (PPAR) gamma agonists ciglitazone or 15-deoxy-Delta 12,14-prostaglandin J2 resulted in a concentration- and time-dependent decrease of cyclin D1 and estrogen receptor (ER) alpha proteins, and this was accompanied by decreased cell proliferation and G(1)-G(0)-->S-phase progression.	9-deoxy-delta-9-prostaglandin D2	134-151	cyclin D1	Homo sapiens	212-221
12615709-1	2003	Treatment of MCF-7 cells with the peroxisome proliferator-activated receptor (PPAR) gamma agonists ciglitazone or 15-deoxy-Delta 12,14-prostaglandin J2 resulted in a concentration- and time-dependent decrease of cyclin D1 and estrogen receptor (ER) alpha proteins, and this was accompanied by decreased cell proliferation and G(1)-G(0)-->S-phase progression.	9-deoxy-delta-9-prostaglandin D2	134-151	estrogen receptor 1	Homo sapiens	226-254
12160520-4	2002	PPARgamma is activated by a wide variety of ligands such as fatty acids, the anti-diabetic thiazolidinediones (TZDs), and also by certain prostaglandins of which 15-deoxy-Delta(12,14)-PGJ2 (PGJ2).	9-deoxy-delta-9-prostaglandin D2	184-188	peroxisome proliferator activated receptor gamma	Homo sapiens	0-9
12595494-6	2003	Activation of PPARgamma with the agonist prostaglandin J2 (10 micro M) and of PPARalpha with either bezafibrate (100 micro M) or Wy14643 (100 micro M) both increased LXRalpha and ABCA1 gene expression also and enhanced apoA1-mediated cholesterol efflux from lipid-loaded cells, even in the presence of IL-1beta.	9-deoxy-delta-9-prostaglandin D2	41-57	peroxisome proliferator activated receptor gamma	Homo sapiens	14-23
12595494-6	2003	Activation of PPARgamma with the agonist prostaglandin J2 (10 micro M) and of PPARalpha with either bezafibrate (100 micro M) or Wy14643 (100 micro M) both increased LXRalpha and ABCA1 gene expression also and enhanced apoA1-mediated cholesterol efflux from lipid-loaded cells, even in the presence of IL-1beta.	9-deoxy-delta-9-prostaglandin D2	41-57	nuclear receptor subfamily 1 group H member 3	Homo sapiens	166-174
12524224-3	2003	METHODS AND RESULTS: The PPARgamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) or ciglitazone, stimulated a PPAR response element-luciferase reporter construct in transfected porcine pulmonary artery endothelial cells (PAECs), demonstrating that PPARgamma was transcriptionally functional.	9-deoxy-delta-9-prostaglandin D2	66-82	peroxisome proliferator activated receptor gamma	Homo sapiens	25-34
12524224-3	2003	METHODS AND RESULTS: The PPARgamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) or ciglitazone, stimulated a PPAR response element-luciferase reporter construct in transfected porcine pulmonary artery endothelial cells (PAECs), demonstrating that PPARgamma was transcriptionally functional.	9-deoxy-delta-9-prostaglandin D2	66-82	peroxisome proliferator activated receptor alpha	Homo sapiens	25-29
12524224-3	2003	METHODS AND RESULTS: The PPARgamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) or ciglitazone, stimulated a PPAR response element-luciferase reporter construct in transfected porcine pulmonary artery endothelial cells (PAECs), demonstrating that PPARgamma was transcriptionally functional.	9-deoxy-delta-9-prostaglandin D2	66-82	peroxisome proliferator activated receptor gamma	Homo sapiens	261-270
12432947-2	2002	The ultimate metabolite of PGD2, 15d-delta(12,14)-PGJ2, specifically binds to a nuclear receptor, the gamma isoform of the peroxisome proliferator-activated receptor, thereby promoting adipogenesis.	9-deoxy-delta-9-prostaglandin D2	49-54	prostaglandin D2 synthase	Homo sapiens	27-31
11955950-0	2002	Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?	9-deoxy-delta-9-prostaglandin D2	34-52	peroxisome proliferator activated receptor gamma	Homo sapiens	19-28
12506134-9	2003	Activation of PPARgamma by the specific agonist PGJ(2) is associated with inhibition of cell proliferation, whereas activation by albumin bound fatty acids is accompanied by increased proliferation.	9-deoxy-delta-9-prostaglandin D2	48-54	peroxisome proliferator activated receptor gamma	Homo sapiens	14-23
12353085-4	2002	The cyclopentenone prostaglandins are naturally occurring prostaglandin D2 (PGD2) derivatives that comprises prostaglandin J2 (PGJ2) and its metabolites delta12-PGJ2 and 15-deoxy- delta12,14-prostaglandin J2 (15d-PGJ2).	9-deoxy-delta-9-prostaglandin D2	109-125	prostaglandin D2 synthase	Homo sapiens	58-74
12353085-4	2002	The cyclopentenone prostaglandins are naturally occurring prostaglandin D2 (PGD2) derivatives that comprises prostaglandin J2 (PGJ2) and its metabolites delta12-PGJ2 and 15-deoxy- delta12,14-prostaglandin J2 (15d-PGJ2).	9-deoxy-delta-9-prostaglandin D2	127-131	prostaglandin D2 synthase	Homo sapiens	58-74
12230869-4	2002	Here we investigated the involvement of HO-1 in the 15d-PGJ(2)-mediated regulation of VEGF production by human microvascular endothelial cells (HMEC-1).	9-deoxy-delta-9-prostaglandin D2	56-62	heme oxygenase 1	Homo sapiens	40-44
12230869-4	2002	Here we investigated the involvement of HO-1 in the 15d-PGJ(2)-mediated regulation of VEGF production by human microvascular endothelial cells (HMEC-1).	9-deoxy-delta-9-prostaglandin D2	56-62	vascular endothelial growth factor A	Homo sapiens	86-90
12432912-8	2002	The induction of COX-2 is suppressed by dexamethasone and PGJ2.	9-deoxy-delta-9-prostaglandin D2	58-62	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	17-22
12160520-6	2002	The aim of this study was to determine whether PGJ2 and TZDs would also exert an immunomodulatory action through the up-regulation of anti-inflammatory cytokines such as the IL-1 receptor antagonist (IL-1Ra).	9-deoxy-delta-9-prostaglandin D2	47-51	interleukin 1 receptor antagonist	Homo sapiens	174-198
12160520-6	2002	The aim of this study was to determine whether PGJ2 and TZDs would also exert an immunomodulatory action through the up-regulation of anti-inflammatory cytokines such as the IL-1 receptor antagonist (IL-1Ra).	9-deoxy-delta-9-prostaglandin D2	47-51	interleukin 1 receptor antagonist	Homo sapiens	200-206
12160520-8	2002	Addition of PGJ2 had an inhibitory effect on IL-1, IL-6 and TNFalpha secretion, while increasing IL-1Ra production.	9-deoxy-delta-9-prostaglandin D2	12-16	interleukin 1 alpha	Homo sapiens	45-49
12160520-8	2002	Addition of PGJ2 had an inhibitory effect on IL-1, IL-6 and TNFalpha secretion, while increasing IL-1Ra production.	9-deoxy-delta-9-prostaglandin D2	12-16	interleukin 6	Homo sapiens	51-55
12160520-8	2002	Addition of PGJ2 had an inhibitory effect on IL-1, IL-6 and TNFalpha secretion, while increasing IL-1Ra production.	9-deoxy-delta-9-prostaglandin D2	12-16	tumor necrosis factor	Homo sapiens	60-68
12160520-8	2002	Addition of PGJ2 had an inhibitory effect on IL-1, IL-6 and TNFalpha secretion, while increasing IL-1Ra production.	9-deoxy-delta-9-prostaglandin D2	12-16	interleukin 1 receptor antagonist	Homo sapiens	97-103
12079830-4	2002	PPARalpha has been shown to bind and to be activated by leukotriene B4 and the hypolipidemic drugs of the fibrate class; PPARbeta/delta ligands are polyunsaturated fatty acids and prostaglandins; while prostaglandin J2 derivatives and the antidiabetic glitazones are, respectively, natural and synthetic ligands for PPARgamma.	9-deoxy-delta-9-prostaglandin D2	202-218	peroxisome proliferator activated receptor alpha	Homo sapiens	0-9
12079830-4	2002	PPARalpha has been shown to bind and to be activated by leukotriene B4 and the hypolipidemic drugs of the fibrate class; PPARbeta/delta ligands are polyunsaturated fatty acids and prostaglandins; while prostaglandin J2 derivatives and the antidiabetic glitazones are, respectively, natural and synthetic ligands for PPARgamma.	9-deoxy-delta-9-prostaglandin D2	202-218	peroxisome proliferator activated receptor delta	Homo sapiens	121-129
12906165-6	2002	Treatment of HUVECs with PPARalpha and PPAR gamma activators--linolenic acid, linoleic acid, oleic acid and prostaglandin J2 respectively, but not with stearic acid could augment PAI-1 mRNA expression and protein secretion in a concentration-dependent manner.	9-deoxy-delta-9-prostaglandin D2	108-124	peroxisome proliferator activated receptor alpha	Homo sapiens	25-34
12906165-6	2002	Treatment of HUVECs with PPARalpha and PPAR gamma activators--linolenic acid, linoleic acid, oleic acid and prostaglandin J2 respectively, but not with stearic acid could augment PAI-1 mRNA expression and protein secretion in a concentration-dependent manner.	9-deoxy-delta-9-prostaglandin D2	108-124	peroxisome proliferator activated receptor gamma	Homo sapiens	39-49
12906165-6	2002	Treatment of HUVECs with PPARalpha and PPAR gamma activators--linolenic acid, linoleic acid, oleic acid and prostaglandin J2 respectively, but not with stearic acid could augment PAI-1 mRNA expression and protein secretion in a concentration-dependent manner.	9-deoxy-delta-9-prostaglandin D2	108-124	serpin family E member 1	Homo sapiens	179-184
12065618-4	2002	The PPARgamma agonists ciglitazone, LY171 833 and prostaglandin-J2, but not the PPARalpha agonist WY14643, inhibited proliferation and induced cell death.	9-deoxy-delta-9-prostaglandin D2	50-66	peroxisome proliferator activated receptor gamma	Homo sapiens	4-13
11950812-6	2002	PPARgamma ligands, 15-deoxy-delta(12,)(14)-prostaglandin J2 (15d-PGJ2) and troglitazone (TGZ), suppressed DNA synthesis of HT-29 cells whereas ligands for PPARalpha and PPARdelta had no significant effects.	9-deoxy-delta-9-prostaglandin D2	43-59	peroxisome proliferator activated receptor gamma	Homo sapiens	0-9
11950812-6	2002	PPARgamma ligands, 15-deoxy-delta(12,)(14)-prostaglandin J2 (15d-PGJ2) and troglitazone (TGZ), suppressed DNA synthesis of HT-29 cells whereas ligands for PPARalpha and PPARdelta had no significant effects.	9-deoxy-delta-9-prostaglandin D2	43-59	peroxisome proliferator activated receptor alpha	Homo sapiens	155-164
11950812-6	2002	PPARgamma ligands, 15-deoxy-delta(12,)(14)-prostaglandin J2 (15d-PGJ2) and troglitazone (TGZ), suppressed DNA synthesis of HT-29 cells whereas ligands for PPARalpha and PPARdelta had no significant effects.	9-deoxy-delta-9-prostaglandin D2	43-59	peroxisome proliferator activated receptor delta	Homo sapiens	169-178
12269390-3	2002	In the present report, we show that the expression of PPARgamma was significantly increased in tumor tissues from human colon cancer compared with non-tumor tissues and that PPARgamma ligands, 15-Deoxy-delta(12,14)prostaglandin J2 or ciglitizone, induced apoptosis in HT-29 cells, a human colon cancer cell line.	9-deoxy-delta-9-prostaglandin D2	214-230	peroxisome proliferator activated receptor gamma	Homo sapiens	54-63
12269390-3	2002	In the present report, we show that the expression of PPARgamma was significantly increased in tumor tissues from human colon cancer compared with non-tumor tissues and that PPARgamma ligands, 15-Deoxy-delta(12,14)prostaglandin J2 or ciglitizone, induced apoptosis in HT-29 cells, a human colon cancer cell line.	9-deoxy-delta-9-prostaglandin D2	214-230	peroxisome proliferator activated receptor gamma	Homo sapiens	174-183
11927655-1	2002	The prostaglandin, 15-deoxy Delta(12,14)-prostaglandin J2 (15d-PGJ2)(1), and thiazolidinediones are ligands for the nuclear receptor, peroxisome proliferator-activated receptor (PPAR)-gamma, which mediates anti-inflammatory activity by suppressing murine macrophage (Mphi) production of the inflammatory mediator, nitric oxide (NO).	9-deoxy-delta-9-prostaglandin D2	63-67	peroxisome proliferator activated receptor gamma	Mus musculus	134-189
11960303-6	2002	In vivo treatment of SJL/J mice with PPARgamma agonists, 15-deoxydelta(12,14) prostaglandin J2 or Ciglitazone, decreased the duration and clinical severity of active immunization and adoptive transfer models of EAE.	9-deoxy-delta-9-prostaglandin D2	78-94	peroxisome proliferator activated receptor gamma	Mus musculus	37-46
11864843-3	2002	This review focuses on recent findings concerning prostaglandin E2 (PGE2) and the PGD2 metabolite 15-deoxy-Delta(12,14)-PGJ2, and their divergent roles in immune regulation.	9-deoxy-delta-9-prostaglandin D2	119-124	prostaglandin D2 synthase	Homo sapiens	82-86
11859145-7	2002	15d-PGJ2 suppressed IFN-gamma, IL-10, and IL-4 production by both Con A- and myelin basic protein Ac(1-11) peptide-stimulated lymphocytes as determined by ELISA and ELISPOT assay.	9-deoxy-delta-9-prostaglandin D2	4-8	interleukin 10	Mus musculus	31-36
11859145-7	2002	15d-PGJ2 suppressed IFN-gamma, IL-10, and IL-4 production by both Con A- and myelin basic protein Ac(1-11) peptide-stimulated lymphocytes as determined by ELISA and ELISPOT assay.	9-deoxy-delta-9-prostaglandin D2	4-8	interleukin 4	Mus musculus	42-46
11859145-7	2002	15d-PGJ2 suppressed IFN-gamma, IL-10, and IL-4 production by both Con A- and myelin basic protein Ac(1-11) peptide-stimulated lymphocytes as determined by ELISA and ELISPOT assay.	9-deoxy-delta-9-prostaglandin D2	4-8	interferon gamma	Mus musculus	20-29
11872377-4	2002	Recently, synthetic antidiabetic thiazolidinediones (TZDs) and the natural prostaglandin D2 (PGD2) metabolite, 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2), have been identified as ligands for PPARgamma.	9-deoxy-delta-9-prostaglandin D2	133-149	prostaglandin D2 synthase	Homo sapiens	75-91
11755918-0	2002	Upregulation of interleukin-8 expression by prostaglandin D2 metabolite 15-deoxy-delta12, 14 prostaglandin J2 (15d-PGJ2) in human THP-1 macrophages.	9-deoxy-delta-9-prostaglandin D2	93-109	C-X-C motif chemokine ligand 8	Homo sapiens	16-29
11755918-0	2002	Upregulation of interleukin-8 expression by prostaglandin D2 metabolite 15-deoxy-delta12, 14 prostaglandin J2 (15d-PGJ2) in human THP-1 macrophages.	9-deoxy-delta-9-prostaglandin D2	93-109	GLI family zinc finger 2	Homo sapiens	130-135
11755918-3	2002	We report for the first time that the expression of human IL-8 gene in THP-1 macrophages is upregulated in a time- and concentration-dependent manner by prostaglandin D2 metabolite 15-deoxy-delta12, 14 prostaglandin J2 (15d-PGJ2), which is a natural ligand for activation of peroxisome proliferator-activated receptor-gamma transcription factor.	9-deoxy-delta-9-prostaglandin D2	202-218	C-X-C motif chemokine ligand 8	Homo sapiens	58-62
11755918-3	2002	We report for the first time that the expression of human IL-8 gene in THP-1 macrophages is upregulated in a time- and concentration-dependent manner by prostaglandin D2 metabolite 15-deoxy-delta12, 14 prostaglandin J2 (15d-PGJ2), which is a natural ligand for activation of peroxisome proliferator-activated receptor-gamma transcription factor.	9-deoxy-delta-9-prostaglandin D2	202-218	GLI family zinc finger 2	Homo sapiens	71-76
11755918-6	2002	In contrast, THP-1 macrophages when treated with pyrrolidine dithiocarbamate, an anti-oxidant and the selective inhibitor for nuclear factor kappaB, showed an enhanced 15d-PGJ2-mediated upregulation of IL-8 gene expression.	9-deoxy-delta-9-prostaglandin D2	171-176	GLI family zinc finger 2	Homo sapiens	13-18
11755918-6	2002	In contrast, THP-1 macrophages when treated with pyrrolidine dithiocarbamate, an anti-oxidant and the selective inhibitor for nuclear factor kappaB, showed an enhanced 15d-PGJ2-mediated upregulation of IL-8 gene expression.	9-deoxy-delta-9-prostaglandin D2	171-176	C-X-C motif chemokine ligand 8	Homo sapiens	202-206
11872377-4	2002	Recently, synthetic antidiabetic thiazolidinediones (TZDs) and the natural prostaglandin D2 (PGD2) metabolite, 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2), have been identified as ligands for PPARgamma.	9-deoxy-delta-9-prostaglandin D2	133-149	peroxisome proliferator activated receptor gamma	Homo sapiens	198-207
11477100-8	2001	Cell death resulted from an apoptotic process, because 15-d-PGJ2-treated hMFs exhibited condensed nuclei, fragmented DNA, and elevated caspase-3 activity.	9-deoxy-delta-9-prostaglandin D2	60-64	caspase 3	Homo sapiens	135-144
11600134-6	2001	Among the various administration routes tested, GST-P became immunohistochemically demonstrable in the liver centrilobular zone 3 after 24-48h on administration of prostaglandin J2"s, 15-deoxy-Delta(12,14)-PGJ2, PGJ2 and Delta(12)-PGJ2 to male rats via the portal vein, whereby the animals had been pretreated with Soya oil intraperitoneally to exhaust fatty acid binding proteins.	9-deoxy-delta-9-prostaglandin D2	164-180	glutathione S-transferase pi 1	Rattus norvegicus	48-53
11600134-6	2001	Among the various administration routes tested, GST-P became immunohistochemically demonstrable in the liver centrilobular zone 3 after 24-48h on administration of prostaglandin J2"s, 15-deoxy-Delta(12,14)-PGJ2, PGJ2 and Delta(12)-PGJ2 to male rats via the portal vein, whereby the animals had been pretreated with Soya oil intraperitoneally to exhaust fatty acid binding proteins.	9-deoxy-delta-9-prostaglandin D2	206-210	glutathione S-transferase pi 1	Rattus norvegicus	48-53
11577781-0	2001	Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-gamma-independent manner.	9-deoxy-delta-9-prostaglandin D2	0-16	C-X-C motif chemokine ligand 8	Homo sapiens	38-51
11728175-3	2001	We also exposed TMS-14 cells to DIG cocktail followed by 15-deoxy Delta(12,14)-prostaglandin J2 (15d-PGJ2), a ligand of PPAR gamma, interleukin- 11 (IL-11), 9-cis retinoic acid (9-cis RA) and vitamin K2.	9-deoxy-delta-9-prostaglandin D2	79-95	peroxisome proliferator activated receptor gamma	Mus musculus	120-130
11577781-0	2001	Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-gamma-independent manner.	9-deoxy-delta-9-prostaglandin D2	0-16	peroxisome proliferator activated receptor gamma	Homo sapiens	78-88
11577781-2	2001	We investigated the influence of PPARgamma-ligands, 15-deoxy-delta12,14 prostaglandin-J2 (15d-PGJ2), and ciglitazone, on the generation of interleukin-8 (IL-8) by the human microvascular endothelial cell line (HMEC- 1).	9-deoxy-delta-9-prostaglandin D2	72-88	C-X-C motif chemokine ligand 8	Homo sapiens	139-152
11728175-3	2001	We also exposed TMS-14 cells to DIG cocktail followed by 15-deoxy Delta(12,14)-prostaglandin J2 (15d-PGJ2), a ligand of PPAR gamma, interleukin- 11 (IL-11), 9-cis retinoic acid (9-cis RA) and vitamin K2.	9-deoxy-delta-9-prostaglandin D2	79-95	interleukin 11	Mus musculus	132-147
11204739-4	2001	Transforming growth factor-beta (1 ng/ml) and 15-deoxy-delta(12,14) prostaglandin J2 (1 microM) significantly (P < 0.05) (33% and 44% respectively) increased PGHS-1 promoter activity.	9-deoxy-delta-9-prostaglandin D2	68-84	prostaglandin-endoperoxide synthase 1	Homo sapiens	161-167
11282151-0	2001	The cyclopentone prostaglandin 15-deoxy-Delta(12,14) prostaglandin J2 represses nitric oxide, TNF-alpha, and IL-12 production by microglial cells.	9-deoxy-delta-9-prostaglandin D2	53-69	tumor necrosis factor	Rattus norvegicus	94-103
11282151-0	2001	The cyclopentone prostaglandin 15-deoxy-Delta(12,14) prostaglandin J2 represses nitric oxide, TNF-alpha, and IL-12 production by microglial cells.	9-deoxy-delta-9-prostaglandin D2	53-69	interleukin 12B	Rattus norvegicus	109-114
11237557-3	2001	We investigated the mechanism by which PGJ(2) inhibits NO production in LPS/IFN-gamma-stimulated MRL/lpr mesangial cells.	9-deoxy-delta-9-prostaglandin D2	39-45	toll-like receptor 4	Mus musculus	72-75
11237557-3	2001	We investigated the mechanism by which PGJ(2) inhibits NO production in LPS/IFN-gamma-stimulated MRL/lpr mesangial cells.	9-deoxy-delta-9-prostaglandin D2	39-45	interferon gamma	Mus musculus	76-85
11390455-1	2001	Ligands for peroxisome proliferator-activated receptor gamma (PPARgamma), such as 15-deoxy-Delta(12,14)PGJ2 (15d-PGJ2) have been proposed as a new class of antiinflammatory compounds with possible clinical applications.	9-deoxy-delta-9-prostaglandin D2	103-107	peroxisome proliferator activated receptor gamma	Homo sapiens	12-60
11390455-1	2001	Ligands for peroxisome proliferator-activated receptor gamma (PPARgamma), such as 15-deoxy-Delta(12,14)PGJ2 (15d-PGJ2) have been proposed as a new class of antiinflammatory compounds with possible clinical applications.	9-deoxy-delta-9-prostaglandin D2	103-107	peroxisome proliferator activated receptor gamma	Homo sapiens	62-71
11301410-1	2001	The cyclopentenone prostaglandins PGA2, PGA1, and PGJ2 are formed by dehydration within the cyclopentane ring of PGE2, PGE1, and PGD2.	9-deoxy-delta-9-prostaglandin D2	50-54	prostaglandin D2 synthase	Homo sapiens	129-133
11205925-4	2001	Using the LA-N-5 nb cell line, we have determined that the natural PPARgamma ligand 15-deoxy-delta prostaglandin J2, as well as the synthetic PPARgamma agonist GW1929, can stimulate the differentiation of nb cells, as evidenced by the inhibition of cell proliferation, neurite outgrowth, increased acetylcholinesterase activity, and the reduction of N-myc expression.	9-deoxy-delta-9-prostaglandin D2	99-115	peroxisome proliferator activated receptor gamma	Homo sapiens	67-76
11089900-7	2000	Furthermore, fatty acids and eicosanoids are natural PPAR ligands: PPARalpha is activated by leukotriene B4, whereas prostaglandin J2 is a PPARgamma ligand.	9-deoxy-delta-9-prostaglandin D2	117-133	peroxisome proliferator activated receptor alpha	Mus musculus	53-57
11242474-2	2000	PPARgamma is bound and activated by fatty acid derivatives and prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	63-79	peroxisome proliferator activated receptor gamma	Homo sapiens	0-9
11374025-6	2001	Furthermore, fatty acid-derivatives and eicosanoids are natural PPAR ligands: PPAR alpha is activated by leukotriene B4, whereas prostaglandin J2 is a PPAR gamma ligand, as well as some components of oxidized LDL, such as 9- and 13-HODE.	9-deoxy-delta-9-prostaglandin D2	129-145	peroxisome proliferator activated receptor alpha	Homo sapiens	64-68
11089900-7	2000	Furthermore, fatty acids and eicosanoids are natural PPAR ligands: PPARalpha is activated by leukotriene B4, whereas prostaglandin J2 is a PPARgamma ligand.	9-deoxy-delta-9-prostaglandin D2	117-133	peroxisome proliferator activated receptor gamma	Mus musculus	139-148
10640767-0	2000	Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists.	9-deoxy-delta-9-prostaglandin D2	61-77	Fas (TNF receptor superfamily member 6)	Mus musculus	49-52
10799521-5	2000	CD34(+) HSCs, but not hMSCs, express PPAR-gamma, and 15-deoxy-Delta(12, 14)-prostaglandin-J2 (15d-PG-J2), a PPAR-gamma agonist, completely blocked the effects of sOPGL and M-CSF on Ocl formation and activity.	9-deoxy-delta-9-prostaglandin D2	74-92	CD34 molecule	Homo sapiens	0-4
10799521-5	2000	CD34(+) HSCs, but not hMSCs, express PPAR-gamma, and 15-deoxy-Delta(12, 14)-prostaglandin-J2 (15d-PG-J2), a PPAR-gamma agonist, completely blocked the effects of sOPGL and M-CSF on Ocl formation and activity.	9-deoxy-delta-9-prostaglandin D2	74-92	colony stimulating factor 1	Homo sapiens	172-177
10987274-6	2000	The yield of Hsp70 purified from 15d-PGJ2-treated cells was 4-5-fold higher when compared with untreated TRAMP-C2 cells.	9-deoxy-delta-9-prostaglandin D2	37-41	heat shock protein 1B	Mus musculus	13-18
11094980-6	2000	The recombinant protein of OPR3 cross-reacted with an antiserum raised against the OYE protein, and showed oxidation of beta-NADPH when OPDA or 15-deoxy-delta(12,14) prostaglandin J2 (PGJ2), an analogue of OPDA, was used as substrate.	9-deoxy-delta-9-prostaglandin D2	166-182	oxophytodienoate-reductase 3	Arabidopsis thaliana	27-31
11094980-6	2000	The recombinant protein of OPR3 cross-reacted with an antiserum raised against the OYE protein, and showed oxidation of beta-NADPH when OPDA or 15-deoxy-delta(12,14) prostaglandin J2 (PGJ2), an analogue of OPDA, was used as substrate.	9-deoxy-delta-9-prostaglandin D2	184-188	oxophytodienoate-reductase 3	Arabidopsis thaliana	27-31
10834301-1	2000	PGD2 and its metabolites PGJ2 and 15-deoxy-delta12,14-PGJ2 have been reported to inhibit iNOS induction in cultured vascular smooth muscle cells.	9-deoxy-delta-9-prostaglandin D2	25-29	nitric oxide synthase 2	Rattus norvegicus	89-93
10753940-8	2000	Hence, we examined the molecular mechanism underlying the 15-deoxy-Delta(12, 14)-PGJ2-induced GSTP1 gene expression.	9-deoxy-delta-9-prostaglandin D2	81-85	glutathione S-transferase pi 1	Rattus norvegicus	94-99
10640767-8	2000	NO production in stimulated MRL/lpr and BALB/c mesangial cells, was blocked by PGJ2 and pioglitazone.	9-deoxy-delta-9-prostaglandin D2	79-83	Fas (TNF receptor superfamily member 6)	Mus musculus	32-35
10640767-9	2000	These studies suggest that abnormalities in PGJ2 production are present in MRL/lpr mice and may be linked to the heightened activation state of mesangial cells in these mice.	9-deoxy-delta-9-prostaglandin D2	44-48	Fas (TNF receptor superfamily member 6)	Mus musculus	79-82
10632585-6	2000	We report that NSAIDs, drugs of the thiazolidinedione class, and the natural ligand prostaglandin J2 act as agonists for PPARgamma and inhibit the beta-amyloid-stimulated secretion of proinflammatory products by microglia and monocytes responsible for neurotoxicity and astrocyte activation.	9-deoxy-delta-9-prostaglandin D2	84-100	peroxisome proliferator activated receptor gamma	Homo sapiens	121-130
10793637-10	2000	The response of the cells to PPAR-gamma agonist 15-deoxy-delta 12,14 prostaglandin J2 (15dPGJ2, 200 and 490 nmol l-1) with and without changing the cell cycle by the anti-apoptogenic drug aurintricarboxylic acid (ATA, 10 mumol l-1) was used as an in vitro model to study the relationship between the cell cycle and PPAR-gamma.	9-deoxy-delta-9-prostaglandin D2	69-85	peroxisome proliferator activated receptor gamma	Bos taurus	29-39
11996104-3	2000	Rat vascular smooth muscle cells (VSMC) and murine macrophages RAW264.7 were incubated for 24 h with PPARgamma activators: prostaglandin J2 and ciglitazone.	9-deoxy-delta-9-prostaglandin D2	123-139	peroxisome proliferator activated receptor gamma	Mus musculus	101-110
11996104-4	2000	PPARgamma were expressed in VSMC and RAW cells and their activity was upregulated in the presence of PGJ2 and ciglitazone.	9-deoxy-delta-9-prostaglandin D2	101-105	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-9
10935488-6	1999	Addition of the RXRalpha ligands, 9-cis-RA or LG100268, sensitized T24 bladder cancer cells to the lethal effect of troglitazone and two other PPAR- activators, ciglitazone and 15-deoxy-delta(12,14)-PGJ2 (15dPGJ(2)).	9-deoxy-delta-9-prostaglandin D2	199-203	retinoid X receptor alpha	Homo sapiens	16-24
10574507-2	1999	PPARgamma is bound and activated by prostaglandin J2 and fatty acid derivatives, which are its natural ligands.	9-deoxy-delta-9-prostaglandin D2	36-52	peroxisome proliferator activated receptor gamma	Homo sapiens	0-9
10695726-5	1999	Since in other cell types, both NSAIDs and PGJ2 can activate the peroxisome proliferator-activated receptor-gamma (PPARgamma) and downregulate cytokine levels and iNOS expression, and since CGCs express PPARgamma in vivo and in vitro, our data suggest that activation of CGC PPARgamma mediates iNOS suppression and reduced cell death.	9-deoxy-delta-9-prostaglandin D2	43-47	peroxisome proliferator activated receptor gamma	Homo sapiens	65-113
10695726-5	1999	Since in other cell types, both NSAIDs and PGJ2 can activate the peroxisome proliferator-activated receptor-gamma (PPARgamma) and downregulate cytokine levels and iNOS expression, and since CGCs express PPARgamma in vivo and in vitro, our data suggest that activation of CGC PPARgamma mediates iNOS suppression and reduced cell death.	9-deoxy-delta-9-prostaglandin D2	43-47	peroxisome proliferator activated receptor gamma	Homo sapiens	115-124
10695726-5	1999	Since in other cell types, both NSAIDs and PGJ2 can activate the peroxisome proliferator-activated receptor-gamma (PPARgamma) and downregulate cytokine levels and iNOS expression, and since CGCs express PPARgamma in vivo and in vitro, our data suggest that activation of CGC PPARgamma mediates iNOS suppression and reduced cell death.	9-deoxy-delta-9-prostaglandin D2	43-47	nitric oxide synthase 2	Homo sapiens	163-167
10695726-5	1999	Since in other cell types, both NSAIDs and PGJ2 can activate the peroxisome proliferator-activated receptor-gamma (PPARgamma) and downregulate cytokine levels and iNOS expression, and since CGCs express PPARgamma in vivo and in vitro, our data suggest that activation of CGC PPARgamma mediates iNOS suppression and reduced cell death.	9-deoxy-delta-9-prostaglandin D2	43-47	peroxisome proliferator activated receptor gamma	Homo sapiens	203-212
10695726-5	1999	Since in other cell types, both NSAIDs and PGJ2 can activate the peroxisome proliferator-activated receptor-gamma (PPARgamma) and downregulate cytokine levels and iNOS expression, and since CGCs express PPARgamma in vivo and in vitro, our data suggest that activation of CGC PPARgamma mediates iNOS suppression and reduced cell death.	9-deoxy-delta-9-prostaglandin D2	43-47	peroxisome proliferator activated receptor gamma	Homo sapiens	203-212
10695726-5	1999	Since in other cell types, both NSAIDs and PGJ2 can activate the peroxisome proliferator-activated receptor-gamma (PPARgamma) and downregulate cytokine levels and iNOS expression, and since CGCs express PPARgamma in vivo and in vitro, our data suggest that activation of CGC PPARgamma mediates iNOS suppression and reduced cell death.	9-deoxy-delta-9-prostaglandin D2	43-47	nitric oxide synthase 2	Homo sapiens	294-298
10222233-0	1999	Prostaglandin J2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells.	9-deoxy-delta-9-prostaglandin D2	0-16	nerve growth factor	Rattus norvegicus	74-93
10509805-7	1999	The effects on PPARalpha mRNA are independent of protein synthesis, whereas inhibition of PPARgamma mRNA expression depends on protein synthesis, except when its specific ligand prostaglandin J2 is used.	9-deoxy-delta-9-prostaglandin D2	178-194	peroxisome proliferator activated receptor gamma	Homo sapiens	90-99
9834460-5	1998	The cells (24 h culture) responded dose dependently by increasing progesterone secretion (up to 1.5-fold of the basal level) to an endogenous ligand of PPARgamma, 15-deoxy-delta12,14 prostaglandin J2 (15-dPGJ2) and to the thiazolidinedione ciglitizone.	9-deoxy-delta-9-prostaglandin D2	183-199	peroxisome proliferator activated receptor gamma	Bos taurus	152-161
10205228-9	1999	No expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) was detected in VSMC, and 15-deoxy-D12,14 prostaglandin J2, the natural ligand for the PPARgamma, did not resemble the effect of troglitazone on IL-1-induced NO synthesis.	9-deoxy-delta-9-prostaglandin D2	120-136	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	165-174
10203248-1	1999	The peroxisome proliferator-activated receptor-gamma (PPARgamma) is activated by 15-deoxy-delta(12,14) prostaglandin J2 (15d-PGJ2), anti-diabetic thiazolidinediones and several non-steroidal anti-inflammatory drugs (NSAIDs).	9-deoxy-delta-9-prostaglandin D2	103-119	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	4-52
10203248-1	1999	The peroxisome proliferator-activated receptor-gamma (PPARgamma) is activated by 15-deoxy-delta(12,14) prostaglandin J2 (15d-PGJ2), anti-diabetic thiazolidinediones and several non-steroidal anti-inflammatory drugs (NSAIDs).	9-deoxy-delta-9-prostaglandin D2	103-119	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	54-63
10076998-10	1999	A natural PPARgamma ligand, 15-deoxy-delta12,14-PGJ2, was also active in this assay with a maximal induction of aP2 mRNA of approximately 5-fold when tested at 1 microM.	9-deoxy-delta-9-prostaglandin D2	48-52	peroxisome proliferator activated receptor gamma	Mus musculus	10-19
10076998-10	1999	A natural PPARgamma ligand, 15-deoxy-delta12,14-PGJ2, was also active in this assay with a maximal induction of aP2 mRNA of approximately 5-fold when tested at 1 microM.	9-deoxy-delta-9-prostaglandin D2	48-52	fatty acid binding protein 4, adipocyte	Mus musculus	112-115
9824682-4	1998	In proportion to the increased c-myc gene transcription, heat shock protein 70 (hsp70) mRNA was induced from 1 to 24 h after PGA2/Delta12-PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	138-142	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	31-36
9824682-4	1998	In proportion to the increased c-myc gene transcription, heat shock protein 70 (hsp70) mRNA was induced from 1 to 24 h after PGA2/Delta12-PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	138-142	heat shock protein family A (Hsp70) member 4	Homo sapiens	57-78
9824682-4	1998	In proportion to the increased c-myc gene transcription, heat shock protein 70 (hsp70) mRNA was induced from 1 to 24 h after PGA2/Delta12-PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	138-142	heat shock protein family A (Hsp70) member 4	Homo sapiens	80-85
9824682-6	1998	Moreover, overexpressed HSP70 showed an increased resistance to apoptosis by PGA2/Delta12-PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	90-94	heat shock protein family A (Hsp70) member 4	Homo sapiens	24-29
9545524-4	1998	The prostaglandins (in order of potency) PGJ2 > PGA1 > PGA2, approximately PGD2 >> PGE2 all significantly repressed IGF-I gene expression.	9-deoxy-delta-9-prostaglandin D2	41-45	insulin-like growth factor 1	Rattus norvegicus	128-133
9792828-0	1998	p53-Independent activation of the gadd45 promoter by Delta12-prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	61-77	tumor protein p53	Homo sapiens	0-3
9792828-0	1998	p53-Independent activation of the gadd45 promoter by Delta12-prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	61-77	growth arrest and DNA damage inducible alpha	Homo sapiens	34-40
9468191-11	1998	These data suggest that PGD2 suppresses NO generation in VSMCs by inhibiting iNOS mRNA expression, most likely through the cascade of the PGJ2 series rather than through the TX receptor or cAMP upregulation.	9-deoxy-delta-9-prostaglandin D2	138-142	nitric oxide synthase 2	Rattus norvegicus	77-81
9579725-15	1998	PGJ2 and delta12-PGJ2, two endogenous metabolites of PGD2, were also tested in this system and shown to be effective agonists with Ki and EC50 values in the nanomolar range for both compounds.	9-deoxy-delta-9-prostaglandin D2	0-4	prostaglandin D2 synthase	Homo sapiens	53-57
9518257-4	1998	PEPCK mRNA is similarly induced by the natural ligand of PPARgamma, the 15-deoxy-delta(12-14) prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	94-110	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	0-5
9518257-4	1998	PEPCK mRNA is similarly induced by the natural ligand of PPARgamma, the 15-deoxy-delta(12-14) prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	94-110	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	57-66
9503406-2	1997	PGD2 is readily dehydrated to produce PGs of the J series, such as PGJ2, delta 12-PGJ2, and 15-deoxy-delta 12, 14-PGJ2.	9-deoxy-delta-9-prostaglandin D2	67-71	prostaglandin D2 synthase	Homo sapiens	0-4
9442016-3	1998	PGJ2 derivatives function as activating ligands for peroxisome proliferator-activated receptor gamma (PPAR gamma), a nuclear hormone receptor that is central to adipogenic determination.	9-deoxy-delta-9-prostaglandin D2	0-4	peroxisome proliferator activated receptor gamma	Homo sapiens	52-100
9442016-3	1998	PGJ2 derivatives function as activating ligands for peroxisome proliferator-activated receptor gamma (PPAR gamma), a nuclear hormone receptor that is central to adipogenic determination.	9-deoxy-delta-9-prostaglandin D2	0-4	peroxisome proliferator activated receptor gamma	Homo sapiens	102-112
9239419-5	1997	9-cis or all-trans retinoic acid, 1,25 dihydroxyvitamin D3, or the PPARgamma ligands prostaglandin J2 or troglitazone did not affect the development of barrier function or epidermal morphology.	9-deoxy-delta-9-prostaglandin D2	85-101	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	67-76
9084911-6	1997	Incubation experiments with PGA2 and PGJ2 (70-600 microM) clearly showed the role of individual GSTs in the conjugation of PGA2 and PGJ2.	9-deoxy-delta-9-prostaglandin D2	132-136	glutathione S-transferase alpha 1	Homo sapiens	96-100
9211064-2	1997	PPAR alpha has been shown to bind and be activated by leukotriene B4 and fibrates, whereas prostaglandin J2 derivatives and the antidiabetic thiazolidinediones, respectively, are natural and synthetic ligands for PPAR gamma.	9-deoxy-delta-9-prostaglandin D2	91-107	peroxisome proliferator activated receptor gamma	Homo sapiens	213-223
9084911-8	1997	For PGJ2, enzyme activities were up to 4.3 (GSTM1a-1a, 70 microM) and up to 3.1 (GSTM1a-1a, 600 microM) times as high.	9-deoxy-delta-9-prostaglandin D2	4-8	glutathione S-transferase mu 1	Homo sapiens	44-53
9084911-0	1997	Stereoselective conjugation of prostaglandin A2 and prostaglandin J2 with glutathione, catalyzed by the human glutathione S-transferases A1-1, A2-2, M1a-1a, and P1-1.	9-deoxy-delta-9-prostaglandin D2	52-68	S100 calcium binding protein A10	Homo sapiens	161-165
9084911-8	1997	For PGJ2, enzyme activities were up to 4.3 (GSTM1a-1a, 70 microM) and up to 3.1 (GSTM1a-1a, 600 microM) times as high.	9-deoxy-delta-9-prostaglandin D2	4-8	glutathione S-transferase mu 1	Homo sapiens	81-90
9084911-14	1997	GSTM1a-1a showed no stereoselectivity with regard to the GSH conjugation of both PGA2 and PGJ2.	9-deoxy-delta-9-prostaglandin D2	90-94	glutathione S-transferase mu 1	Homo sapiens	0-9
9084911-3	1997	In the present study, the role of the major human GSTs in the conjugation of PGA2 and PGJ2 with GSH was investigated with purified enzymes, i.e., the Alpha-class enzymes GST A1-1 and GST A2-2, the Mu-class enzyme GST M1a-1a, and the Pi-class enzyme GST P1-1.	9-deoxy-delta-9-prostaglandin D2	86-90	glutathione S-transferase alpha 1	Homo sapiens	50-54
9084911-15	1997	GSTA2-2 only showed some minor formation of the R-GSH conjugate of PGJ2.	9-deoxy-delta-9-prostaglandin D2	67-71	glutathione S-transferase alpha 2	Homo sapiens	0-7
9084911-3	1997	In the present study, the role of the major human GSTs in the conjugation of PGA2 and PGJ2 with GSH was investigated with purified enzymes, i.e., the Alpha-class enzymes GST A1-1 and GST A2-2, the Mu-class enzyme GST M1a-1a, and the Pi-class enzyme GST P1-1.	9-deoxy-delta-9-prostaglandin D2	86-90	glutathione S-transferase alpha 1	Homo sapiens	170-178
8521498-0	1995	A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.	9-deoxy-delta-9-prostaglandin D2	2-18	peroxisome proliferator activated receptor gamma	Homo sapiens	36-84
9084911-3	1997	In the present study, the role of the major human GSTs in the conjugation of PGA2 and PGJ2 with GSH was investigated with purified enzymes, i.e., the Alpha-class enzymes GST A1-1 and GST A2-2, the Mu-class enzyme GST M1a-1a, and the Pi-class enzyme GST P1-1.	9-deoxy-delta-9-prostaglandin D2	86-90	glutathione S-transferase alpha 2	Homo sapiens	183-191
9084911-3	1997	In the present study, the role of the major human GSTs in the conjugation of PGA2 and PGJ2 with GSH was investigated with purified enzymes, i.e., the Alpha-class enzymes GST A1-1 and GST A2-2, the Mu-class enzyme GST M1a-1a, and the Pi-class enzyme GST P1-1.	9-deoxy-delta-9-prostaglandin D2	86-90	glutathione S-transferase pi 1	Homo sapiens	249-257
9084911-6	1997	Incubation experiments with PGA2 and PGJ2 (70-600 microM) clearly showed the role of individual GSTs in the conjugation of PGA2 and PGJ2.	9-deoxy-delta-9-prostaglandin D2	37-41	glutathione S-transferase alpha 1	Homo sapiens	96-100
9089005-4	1996	In the present study the PGA1/PGJ2-dependent growth inhibition of IL-2-stimulated primary human cord blood mononuclear cells (CBMCs) was found to be mediated by interference with the IL-2 proliferative signal.	9-deoxy-delta-9-prostaglandin D2	30-34	interleukin 2	Homo sapiens	66-70
9089005-4	1996	In the present study the PGA1/PGJ2-dependent growth inhibition of IL-2-stimulated primary human cord blood mononuclear cells (CBMCs) was found to be mediated by interference with the IL-2 proliferative signal.	9-deoxy-delta-9-prostaglandin D2	30-34	interleukin 2	Homo sapiens	183-187
9089005-6	1996	PGA1 and even more PGJ2 downregulated the expression of IL-2 receptor alpha (CD25 phenotype).	9-deoxy-delta-9-prostaglandin D2	19-23	interleukin 2 receptor subunit alpha	Homo sapiens	56-75
8908616-5	1996	Furthermore, PGJ2 induced a rapid and transient expression of apoptosis-related protooncogene, c-fos, in both cells.	9-deoxy-delta-9-prostaglandin D2	13-17	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	95-100
8908616-8	1996	These data suggest that PGJ2 can induce apoptosis of human leukemia/lymphoma cells and the rapid activation of c-fos protooncogene transcription in which de novo protein synthesis is not required.	9-deoxy-delta-9-prostaglandin D2	24-28	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	111-116
8663202-4	1996	Delta12-PGJ2 markedly stimulated the expression of the BiP gene in a time- and concentration-dependent manner in HeLa cells.	9-deoxy-delta-9-prostaglandin D2	8-12	heat shock protein family A (Hsp70) member 5	Homo sapiens	55-58
8663202-6	1996	Cycloheximide pretreatment completely inhibited the Delta12-PGJ2-induced expression of the BiP gene, suggesting that the effects on nascent protein synthesis are involved in the signaling mechanism.	9-deoxy-delta-9-prostaglandin D2	60-64	heat shock protein family A (Hsp70) member 5	Homo sapiens	91-94
8725145-2	1996	Although peroxisome proliferators, including fibrates and fatty acids, activate the transcriptional activity of these receptors, only prostaglandin J2 derivatives have been identified as natural ligands of the PPAR gamma subtype that also binds thiazolidinedione antidiabetic agents with high affinity.	9-deoxy-delta-9-prostaglandin D2	134-150	peroxisome proliferator activated receptor gamma	Homo sapiens	210-220
8931117-0	1996	Stimulation of tumor necrosis factor-alpha release from lipopolysaccharide-activated human blood monocytes by prostaglandin J2 and metabolites of prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	110-126	tumor necrosis factor	Homo sapiens	15-42
8931117-0	1996	Stimulation of tumor necrosis factor-alpha release from lipopolysaccharide-activated human blood monocytes by prostaglandin J2 and metabolites of prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	146-162	tumor necrosis factor	Homo sapiens	15-42
8931117-3	1996	All PGJ2 compounds stimulated TNF-alpha-release from lipopolysaccharide-activated monocytes.	9-deoxy-delta-9-prostaglandin D2	4-8	tumor necrosis factor	Homo sapiens	30-39
8695669-2	1996	Although peroxisome proliferators, including fibrates and fatty acids, activate the transcriptional activity of these receptors, only prostaglandin J2 derivatives have been identified as natural ligands of the PPAR gamma subtype, which also binds thiazolidinedione antidiabetic agents with high affinity.	9-deoxy-delta-9-prostaglandin D2	134-150	peroxisome proliferator activated receptor gamma	Homo sapiens	210-220
8873236-3	1996	The delta 12-PGJ2-induced apoptosis was augmented by GSH depletion resulted from pretreatment with buthioninine sulfoximine (BSO), an inhibitor of gamma-glutamylcysteine synthetase.	9-deoxy-delta-9-prostaglandin D2	13-17	glutamate-cysteine ligase catalytic subunit	Homo sapiens	147-180
8645293-7	1996	Thus, delta 12-PGJ2 induces PDI gene expression through a pathway independent of de novo protein synthesis.	9-deoxy-delta-9-prostaglandin D2	15-19	prolyl 4-hydroxylase subunit beta	Homo sapiens	28-31
8521498-3	1995	Here, we report the PGJ2 and its derivatives are efficacious activators of peroxisome proliferator-activated receptors alpha and gamma (PPAR alpha and PPAR gamma, respectively), orphan nuclear receptors implicated in lipid homeostasis and adipocyte differentiation.	9-deoxy-delta-9-prostaglandin D2	20-24	peroxisome proliferator activated receptor alpha	Homo sapiens	136-146
8521498-3	1995	Here, we report the PGJ2 and its derivatives are efficacious activators of peroxisome proliferator-activated receptors alpha and gamma (PPAR alpha and PPAR gamma, respectively), orphan nuclear receptors implicated in lipid homeostasis and adipocyte differentiation.	9-deoxy-delta-9-prostaglandin D2	20-24	peroxisome proliferator activated receptor gamma	Homo sapiens	151-161
8521498-4	1995	The PGJ2 metabolite 15-deoxy-delta 12,14-PGJ2 binds directly to PPAR gamma and promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes.	9-deoxy-delta-9-prostaglandin D2	4-8	peroxisome proliferator activated receptor gamma	Homo sapiens	64-74
1375619-3	1992	Immunoblot analysis using a monoclonal antibody specific for the 72-kD heat shock protein (HSP72) revealed that a 12-h incubation with 5 micrograms/ml of delta 12-PGJ2 induced HSP72 formation in HSC-I cells.	9-deoxy-delta-9-prostaglandin D2	163-167	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	71-89
7556684-4	1995	Here we further examined the molecular mechanism underlying the delta 12-PGJ2-induced HO-1 gene expression.	9-deoxy-delta-9-prostaglandin D2	73-77	heme oxygenase 1	Rattus norvegicus	86-90
7556684-7	1995	These findings suggest that delta 12-PGJ2 induces the expression of the HO-1 gene through phosphorylation of the nuclear proteins which bind to the delta 12-PGJ2-responsive element.	9-deoxy-delta-9-prostaglandin D2	37-41	heme oxygenase 1	Rattus norvegicus	72-76
1417983-8	1992	These results demonstrate that intracellular GSH suppresses delta 12-PGJ2-induced heme oxygenase and p67 syntheses by inhibiting the binding of delta 12-PGJ2 to nuclei.	9-deoxy-delta-9-prostaglandin D2	69-73	CD33 molecule	Homo sapiens	101-104
7630918-4	1995	Immunoblot analysis using a monoclonal antibody specific to human E-cadherin revealed that a 12-h incubation with 5 micrograms/ml of delta 12-PGJ2 induced E-cadherin expression in HSC-1 cells.	9-deoxy-delta-9-prostaglandin D2	142-146	cadherin 1	Homo sapiens	66-76
7630918-4	1995	Immunoblot analysis using a monoclonal antibody specific to human E-cadherin revealed that a 12-h incubation with 5 micrograms/ml of delta 12-PGJ2 induced E-cadherin expression in HSC-1 cells.	9-deoxy-delta-9-prostaglandin D2	142-146	cadherin 1	Homo sapiens	155-165
7965771-6	1994	Treatment with PGA1 and especially with PGJ2 enhanced the synthesis of HSP70 in all these cells.	9-deoxy-delta-9-prostaglandin D2	40-44	heat shock protein family A (Hsp70) member 4	Homo sapiens	71-76
7965771-9	1994	Treatment with PGA1 and even more with PGJ2 remarkably enhanced the synthesis of HSP70 in virus-exposed U937 cells, thus resulting in persistently high levels of HSP70 protein in the cells.	9-deoxy-delta-9-prostaglandin D2	39-43	heat shock protein family A (Hsp70) member 4	Homo sapiens	81-86
7965771-9	1994	Treatment with PGA1 and even more with PGJ2 remarkably enhanced the synthesis of HSP70 in virus-exposed U937 cells, thus resulting in persistently high levels of HSP70 protein in the cells.	9-deoxy-delta-9-prostaglandin D2	39-43	heat shock protein family A (Hsp70) member 4	Homo sapiens	162-167
11539936-5	1993	More importantly, when S-49 cyc- cells were exposed to PGJ2, the adenylate cyclase (cyc-) mutant had decreased DNA synthesis with no change in its nominal cAMP content.	9-deoxy-delta-9-prostaglandin D2	55-59	peptidylprolyl isomerase A, pseudogene 1	Mus musculus	75-89
1375619-3	1992	Immunoblot analysis using a monoclonal antibody specific for the 72-kD heat shock protein (HSP72) revealed that a 12-h incubation with 5 micrograms/ml of delta 12-PGJ2 induced HSP72 formation in HSC-I cells.	9-deoxy-delta-9-prostaglandin D2	163-167	heat shock protein family A (Hsp70) member 1A	Homo sapiens	91-96
1375619-3	1992	Immunoblot analysis using a monoclonal antibody specific for the 72-kD heat shock protein (HSP72) revealed that a 12-h incubation with 5 micrograms/ml of delta 12-PGJ2 induced HSP72 formation in HSC-I cells.	9-deoxy-delta-9-prostaglandin D2	163-167	heat shock protein family A (Hsp70) member 1A	Homo sapiens	176-181
1375619-5	1992	The quantity of HSP72 produced was markedly decreased by co-treatment with 1 microgram/ml of cycloheximide in delta 12-PGJ2-treated cells, and similarly reduced in HSC-I cells following heat treatment.	9-deoxy-delta-9-prostaglandin D2	119-123	heat shock protein family A (Hsp70) member 1A	Homo sapiens	16-21
1582730-5	1992	PGJ2 and delta 12-PGJ2, which are metabolites of PGD2, also stimulated the PHA response in a dose-dependent manner between 10(-6) and 10(-8) M, and had a significant stimulatory effect at 10(-6) and 10(-7) M. The degree of the stimulatory effect was most marked with the PGD2 series among the antineoplastic PGs examined in this study.	9-deoxy-delta-9-prostaglandin D2	0-4	prostaglandin D2 synthase	Homo sapiens	49-53
1592539-9	1992	However, synthesis of HSP70 was induced to a much greater extent by PGJ2 than by PGA1 at the same concentration.	9-deoxy-delta-9-prostaglandin D2	68-72	heat shock protein family A (Hsp70) member 4	Homo sapiens	22-27
1592539-10	1992	Neither PGA1 or PGJ2 inhibited the transcription of HTLV-I in MT-2 cells, but treatment with PGJ2, and not with PGA1, moderately inhibited the synthesis of viral proteins, i.e., p40 Tax and p19 core proteins.	9-deoxy-delta-9-prostaglandin D2	93-97	p40	Human T-cell leukemia virus type I	178-181
1582730-5	1992	PGJ2 and delta 12-PGJ2, which are metabolites of PGD2, also stimulated the PHA response in a dose-dependent manner between 10(-6) and 10(-8) M, and had a significant stimulatory effect at 10(-6) and 10(-7) M. The degree of the stimulatory effect was most marked with the PGD2 series among the antineoplastic PGs examined in this study.	9-deoxy-delta-9-prostaglandin D2	0-4	prostaglandin D2 synthase	Homo sapiens	271-275
34897744-0	2022	Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Delta12,14 PGJ2.	9-deoxy-delta-9-prostaglandin D2	145-149	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	61-98
1867634-1	1991	Prostaglandin (PG) D2 and PGJ2 stimulated porcine aortic endothelial cells to synthesize a 31,000-dalton protein (termed p31) in a time- and concentration-dependent manner.	9-deoxy-delta-9-prostaglandin D2	26-30	ATPase H+ transporting V1 subunit E1	Rattus norvegicus	121-124
1867634-2	1991	The induction of p31 synthesis was specific for PGD2, PGJ2 and PGA1 among the various PGs tested.	9-deoxy-delta-9-prostaglandin D2	54-58	ATPase H+ transporting V1 subunit E1	Rattus norvegicus	17-20
1867634-4	1991	Using two-dimensional polyacrylamide gel electrophoresis, p31 induced by PGJ2 had an isoelectric point of 5.4, which overlapped exactly with that induced by by arsenite.	9-deoxy-delta-9-prostaglandin D2	73-77	ATPase H+ transporting V1 subunit E1	Rattus norvegicus	58-61
1867634-7	1991	The data obtained from this study suggest that p31 induced by PGD2 and PGJ2 may play a role in the metabolic regulation of many mammalian cells.	9-deoxy-delta-9-prostaglandin D2	71-75	proteasome 26S subunit, non-ATPase 8	Homo sapiens	47-50
33033709-4	2020	Treatment of human breast cancer MCF-7 cells with 15d-PGJ2 induced EMT as evidenced by increased expression of Snail and ZEB1, with concurrent down-regulation of E-cadherin.	9-deoxy-delta-9-prostaglandin D2	54-58	snail family transcriptional repressor 1	Homo sapiens	111-116
33033709-4	2020	Treatment of human breast cancer MCF-7 cells with 15d-PGJ2 induced EMT as evidenced by increased expression of Snail and ZEB1, with concurrent down-regulation of E-cadherin.	9-deoxy-delta-9-prostaglandin D2	54-58	zinc finger E-box binding homeobox 1	Homo sapiens	121-125
33033709-4	2020	Treatment of human breast cancer MCF-7 cells with 15d-PGJ2 induced EMT as evidenced by increased expression of Snail and ZEB1, with concurrent down-regulation of E-cadherin.	9-deoxy-delta-9-prostaglandin D2	54-58	cadherin 1	Homo sapiens	162-172
33033709-5	2020	Nuclear extract from 15d-PGJ2-treated MCF-7 cells showed the binding of Snail and ZEB1 to E-box sequences present in the E-cadherin promoter, which accounts for repression of E-catherin expression.	9-deoxy-delta-9-prostaglandin D2	25-29	snail family transcriptional repressor 1	Homo sapiens	72-77
33033709-5	2020	Nuclear extract from 15d-PGJ2-treated MCF-7 cells showed the binding of Snail and ZEB1 to E-box sequences present in the E-cadherin promoter, which accounts for repression of E-catherin expression.	9-deoxy-delta-9-prostaglandin D2	25-29	zinc finger E-box binding homeobox 1	Homo sapiens	82-86
33033709-5	2020	Nuclear extract from 15d-PGJ2-treated MCF-7 cells showed the binding of Snail and ZEB1 to E-box sequences present in the E-cadherin promoter, which accounts for repression of E-catherin expression.	9-deoxy-delta-9-prostaglandin D2	25-29	cadherin 1	Homo sapiens	121-131
33033709-7	2020	Notably, the mRNA level of interleukin-8 (IL-8)/CXCL8 was highly elevated in 15d-PGJ2-stimulated MCF-7 cells.	9-deoxy-delta-9-prostaglandin D2	81-85	C-X-C motif chemokine ligand 8	Homo sapiens	27-40
33033709-7	2020	Notably, the mRNA level of interleukin-8 (IL-8)/CXCL8 was highly elevated in 15d-PGJ2-stimulated MCF-7 cells.	9-deoxy-delta-9-prostaglandin D2	81-85	C-X-C motif chemokine ligand 8	Homo sapiens	42-46
33033709-7	2020	Notably, the mRNA level of interleukin-8 (IL-8)/CXCL8 was highly elevated in 15d-PGJ2-stimulated MCF-7 cells.	9-deoxy-delta-9-prostaglandin D2	81-85	C-X-C motif chemokine ligand 8	Homo sapiens	48-53
33033709-11	2020	Taken together, above findings suggest that 15d-PGJ2 induces EMT through up-regulation of Snail expression and subsequent production of CXCL8 as a putative activator of fibroblasts, which may contribute to tumor-stroma interaction in inflammatory breast cancer microenvironment.	9-deoxy-delta-9-prostaglandin D2	48-52	snail family transcriptional repressor 1	Homo sapiens	90-95
33033709-11	2020	Taken together, above findings suggest that 15d-PGJ2 induces EMT through up-regulation of Snail expression and subsequent production of CXCL8 as a putative activator of fibroblasts, which may contribute to tumor-stroma interaction in inflammatory breast cancer microenvironment.	9-deoxy-delta-9-prostaglandin D2	48-52	C-X-C motif chemokine ligand 8	Homo sapiens	136-141
34332056-2	2021	Although PPAR-gamma mediates some actions of 15d-PGJ2, many actions of 15d-PGJ2 are independent of PPAR-gamma.	9-deoxy-delta-9-prostaglandin D2	49-53	peroxisome proliferator activated receptor gamma	Homo sapiens	9-19
34626868-6	2021	During the gestational period, pioglitazone or PGJ2 suppressed mRNA IFNgamma and IL-10 transcript and protein abundances (in the tissue and culture media), whereas there was an enhanced NF-kappaB protein abundance (in the tissue).	9-deoxy-delta-9-prostaglandin D2	47-51	interferon gamma	Sus scrofa	68-76
34626868-6	2021	During the gestational period, pioglitazone or PGJ2 suppressed mRNA IFNgamma and IL-10 transcript and protein abundances (in the tissue and culture media), whereas there was an enhanced NF-kappaB protein abundance (in the tissue).	9-deoxy-delta-9-prostaglandin D2	47-51	IL10	Sus scrofa	81-86
34703823-10	2021	Site-directed mutagenesis of STAT3 identified Cys259 to be the critical amino acid for the 15d-PGJ2-induced apoptosis as well as epithelial-to-mesenchymal transition.	9-deoxy-delta-9-prostaglandin D2	95-99	signal transducer and activator of transcription 3	Homo sapiens	29-34
34417577-4	2022	Surprisingly, TFEB promotes rather than inhibits apoptosis in response to 15d-PGJ2.	9-deoxy-delta-9-prostaglandin D2	77-82	transcription factor EB	Homo sapiens	14-18
34557159-6	2021	Activation of ERalpha or inhibition of ERbeta significantly downregulated the production of PGJ2, 15(S)-HETE and 13(S)-HODE, whereas inhibition of ERalpha or activation of ERbeta markedly upregulated the production of these three ligands.	9-deoxy-delta-9-prostaglandin D2	92-96	estrogen receptor 1	Homo sapiens	14-21
34557159-6	2021	Activation of ERalpha or inhibition of ERbeta significantly downregulated the production of PGJ2, 15(S)-HETE and 13(S)-HODE, whereas inhibition of ERalpha or activation of ERbeta markedly upregulated the production of these three ligands.	9-deoxy-delta-9-prostaglandin D2	92-96	estrogen receptor 1	Homo sapiens	39-45
34557159-8	2021	Conclusion: The levels of endogenous PPARgamma ligands PGJ2 and 15(S)-HETE are significantly decreased in PTC.	9-deoxy-delta-9-prostaglandin D2	55-59	peroxisome proliferator activated receptor gamma	Homo sapiens	37-46
34417577-5	2022	Mechanistically, ROS-mediated TFEB translocation into the nucleus transcriptionally upregulates the expression of ATF4, which is required for apoptosis elicited by 15d-PGJ2.	9-deoxy-delta-9-prostaglandin D2	168-172	transcription factor EB	Homo sapiens	30-34
34417577-5	2022	Mechanistically, ROS-mediated TFEB translocation into the nucleus transcriptionally upregulates the expression of ATF4, which is required for apoptosis elicited by 15d-PGJ2.	9-deoxy-delta-9-prostaglandin D2	168-172	activating transcription factor 4	Homo sapiens	114-118
35445291-4	2022	Here, we report the nearly complete 1H, 13C, and 15N backbone and side chain resonance assignments of the L-PGDS/PGJ2 complex and the binding site for PGJ2 on L-PGDS.	9-deoxy-delta-9-prostaglandin D2	113-117	prostaglandin D2 synthase	Homo sapiens	106-112
35445291-4	2022	Here, we report the nearly complete 1H, 13C, and 15N backbone and side chain resonance assignments of the L-PGDS/PGJ2 complex and the binding site for PGJ2 on L-PGDS.	9-deoxy-delta-9-prostaglandin D2	151-155	prostaglandin D2 synthase	Homo sapiens	106-112
35445291-0	2022	NMR resonance assignments of mouse lipocalin-type prostaglandin D synthase/prostaglandin J2 complex.	9-deoxy-delta-9-prostaglandin D2	75-91	prostaglandin D2 synthase (brain)	Mus musculus	35-74
35445291-4	2022	Here, we report the nearly complete 1H, 13C, and 15N backbone and side chain resonance assignments of the L-PGDS/PGJ2 complex and the binding site for PGJ2 on L-PGDS.	9-deoxy-delta-9-prostaglandin D2	151-155	prostaglandin D2 synthase	Homo sapiens	159-165
35453404-9	2022	We further demonstrated that phosphorylation of c-Jun N-terminal kinase (JNK)1/2 participated in 15d-PGJ2-upregulated HO-1 expression, which was blocked by SP600125 or Rottlerin.	9-deoxy-delta-9-prostaglandin D2	101-105	mitogen-activated protein kinase 8	Mus musculus	73-80
35453404-9	2022	We further demonstrated that phosphorylation of c-Jun N-terminal kinase (JNK)1/2 participated in 15d-PGJ2-upregulated HO-1 expression, which was blocked by SP600125 or Rottlerin.	9-deoxy-delta-9-prostaglandin D2	101-105	heme oxygenase 1	Mus musculus	118-122
2813398-2	1989	p74 synthesis was stimulated at doses of PGA1 and PGJ2 that inhibited cell replication, and its accumulation ceased upon removal of the PG-induced proliferation block.	9-deoxy-delta-9-prostaglandin D2	50-54	spermatid perinuclear RNA binding protein	Homo sapiens	0-3
35380292-9	2022	RESULTS: Serum creatinine, urea nitrogen and glucose, and PPARgamma and GLUT1 expression in rat PF model were reduced by PPARgamma agonists Rosiglitazone or 15d-PGJ2 and elevated by antagonist GW9662.	9-deoxy-delta-9-prostaglandin D2	160-165	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	58-67
35380292-9	2022	RESULTS: Serum creatinine, urea nitrogen and glucose, and PPARgamma and GLUT1 expression in rat PF model were reduced by PPARgamma agonists Rosiglitazone or 15d-PGJ2 and elevated by antagonist GW9662.	9-deoxy-delta-9-prostaglandin D2	160-165	solute carrier family 2 member 1	Rattus norvegicus	72-77
35380292-9	2022	RESULTS: Serum creatinine, urea nitrogen and glucose, and PPARgamma and GLUT1 expression in rat PF model were reduced by PPARgamma agonists Rosiglitazone or 15d-PGJ2 and elevated by antagonist GW9662.	9-deoxy-delta-9-prostaglandin D2	160-165	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	121-130
34997457-0	2022	Involvement of FoxO1, Sp1, and Nrf2 in Upregulation of Negative Regulator of ROS by 15d-PGJ2 Attenuates H2O2-Induced IL-6 Expression in Rat Brain Astrocytes.	9-deoxy-delta-9-prostaglandin D2	88-92	interleukin 6	Rattus norvegicus	117-121
34997457-9	2022	15d-PGJ2-induced NRROS expression was mediated through PI3K/Akt-dependent activation of Sp1 and FoxO1 and established the essential promoter regions.	9-deoxy-delta-9-prostaglandin D2	4-8	negative regulator of reactive oxygen species	Rattus norvegicus	17-22
34997457-9	2022	15d-PGJ2-induced NRROS expression was mediated through PI3K/Akt-dependent activation of Sp1 and FoxO1 and established the essential promoter regions.	9-deoxy-delta-9-prostaglandin D2	4-8	AKT serine/threonine kinase 1	Rattus norvegicus	60-63
34997457-9	2022	15d-PGJ2-induced NRROS expression was mediated through PI3K/Akt-dependent activation of Sp1 and FoxO1 and established the essential promoter regions.	9-deoxy-delta-9-prostaglandin D2	4-8	forkhead box O1	Rattus norvegicus	96-101
34997457-14	2022	These results confirmed the mechanisms underlying 15d-PGJ2-induced NRROS expression which might be a potential strategy for prevention and management of brain inflammatory and neurodegenerative diseases.	9-deoxy-delta-9-prostaglandin D2	54-58	negative regulator of reactive oxygen species	Rattus norvegicus	67-72
34997457-0	2022	Involvement of FoxO1, Sp1, and Nrf2 in Upregulation of Negative Regulator of ROS by 15d-PGJ2 Attenuates H2O2-Induced IL-6 Expression in Rat Brain Astrocytes.	9-deoxy-delta-9-prostaglandin D2	88-92	forkhead box O1	Rattus norvegicus	15-20
34997457-0	2022	Involvement of FoxO1, Sp1, and Nrf2 in Upregulation of Negative Regulator of ROS by 15d-PGJ2 Attenuates H2O2-Induced IL-6 Expression in Rat Brain Astrocytes.	9-deoxy-delta-9-prostaglandin D2	88-92	NFE2 like bZIP transcription factor 2	Rattus norvegicus	31-35
2930558-3	1989	Of the PGs tested, PGD2 has a remarkable stimulatory activity on osteoblast calcification, but that the effective form is probably a metabolite, delta 12-PGJ2.	9-deoxy-delta-9-prostaglandin D2	154-158	prostaglandin D2 synthase	Homo sapiens	19-23
2751699-5	1989	Prostaglandin J2 was a surprisingly potent competitor for binding to the PGF2 alpha receptor.	9-deoxy-delta-9-prostaglandin D2	0-16	prostaglandin F receptor	Homo sapiens	73-92
33200588-7	2020	RESULTS: Voltage-dependent anion channel 1 (VDAC1) was identified as one of membrane targets for 15d-PGJ2 .	9-deoxy-delta-9-prostaglandin D2	101-105	voltage dependent anion channel 1	Homo sapiens	9-42
32694760-0	2021	Oral administration of curcumin ameliorates pulmonary fibrosis in mice through 15d-PGJ2-mediated induction of hepatocyte growth factor in the colon.	9-deoxy-delta-9-prostaglandin D2	83-87	hepatocyte growth factor	Mus musculus	110-134
33452674-3	2021	15d-PGJ2 inhibits phosphorylation, dimerization, nuclear translocation, and transcriptional activity of STAT3 in H-Ras-transformed human mammary epithelial cells (MCF10A-Ras) through the Michael addition reaction at cysteine 259 of STAT3.	9-deoxy-delta-9-prostaglandin D2	4-8	signal transducer and activator of transcription 3	Homo sapiens	104-109
33452674-3	2021	15d-PGJ2 inhibits phosphorylation, dimerization, nuclear translocation, and transcriptional activity of STAT3 in H-Ras-transformed human mammary epithelial cells (MCF10A-Ras) through the Michael addition reaction at cysteine 259 of STAT3.	9-deoxy-delta-9-prostaglandin D2	4-8	HRas proto-oncogene, GTPase	Homo sapiens	113-118
33452674-3	2021	15d-PGJ2 inhibits phosphorylation, dimerization, nuclear translocation, and transcriptional activity of STAT3 in H-Ras-transformed human mammary epithelial cells (MCF10A-Ras) through the Michael addition reaction at cysteine 259 of STAT3.	9-deoxy-delta-9-prostaglandin D2	4-8	signal transducer and activator of transcription 3	Homo sapiens	232-237
2910843-10	1989	Aldehyde reductase catalyzed the reduction of PGJ2, delta 12-PGJ2, PGH2, or PGA2, but not that of PGB2, PGD2, or PGE2, whereas PGF synthetase reduced PGD2.	9-deoxy-delta-9-prostaglandin D2	46-50	aldo-keto reductase family 1 member A1	Homo sapiens	0-18
33200588-7	2020	RESULTS: Voltage-dependent anion channel 1 (VDAC1) was identified as one of membrane targets for 15d-PGJ2 .	9-deoxy-delta-9-prostaglandin D2	101-105	voltage dependent anion channel 1	Homo sapiens	44-49
33200588-10	2020	VDAC1 was partially colocalized with membrane targets for 15d-PGJ2 .	9-deoxy-delta-9-prostaglandin D2	62-66	voltage dependent anion channel 1	Homo sapiens	0-5
31902920-12	2020	Further, 15d-PGJ2 appeared to suppress cell migration via inactivation of FAK and subsequent disassembly of focal adhesion.	9-deoxy-delta-9-prostaglandin D2	13-17	protein tyrosine kinase 2	Homo sapiens	74-77
32350523-10	2020	Increased production of prostaglandin J2 (PGJ2) activates peroxisome proliferator-activated receptor gamma (PPARg) dependent repression of Wnt expression, while increased production of prostaglandin E2 (PGE2) promotes the differentiation of SEPs.	9-deoxy-delta-9-prostaglandin D2	24-40	peroxisome proliferator activated receptor gamma	Mus musculus	58-106
32350523-10	2020	Increased production of prostaglandin J2 (PGJ2) activates peroxisome proliferator-activated receptor gamma (PPARg) dependent repression of Wnt expression, while increased production of prostaglandin E2 (PGE2) promotes the differentiation of SEPs.	9-deoxy-delta-9-prostaglandin D2	24-40	peroxisome proliferator activated receptor gamma	Mus musculus	108-113
32350523-10	2020	Increased production of prostaglandin J2 (PGJ2) activates peroxisome proliferator-activated receptor gamma (PPARg) dependent repression of Wnt expression, while increased production of prostaglandin E2 (PGE2) promotes the differentiation of SEPs.	9-deoxy-delta-9-prostaglandin D2	42-46	peroxisome proliferator activated receptor gamma	Mus musculus	58-106
32350523-10	2020	Increased production of prostaglandin J2 (PGJ2) activates peroxisome proliferator-activated receptor gamma (PPARg) dependent repression of Wnt expression, while increased production of prostaglandin E2 (PGE2) promotes the differentiation of SEPs.	9-deoxy-delta-9-prostaglandin D2	42-46	peroxisome proliferator activated receptor gamma	Mus musculus	108-113
32647651-10	2020	Based on these findings, we propose that 15d-PGJ2 inactivates IKKbeta-NuF-kappaB signaling through oxidative or covalent modification of IKKbeta, thereby inducing apoptosis in Ha-ras transformed human breast epithelial cells.	9-deoxy-delta-9-prostaglandin D2	45-49	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	62-69
32647651-10	2020	Based on these findings, we propose that 15d-PGJ2 inactivates IKKbeta-NuF-kappaB signaling through oxidative or covalent modification of IKKbeta, thereby inducing apoptosis in Ha-ras transformed human breast epithelial cells.	9-deoxy-delta-9-prostaglandin D2	45-49	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	137-144
28372990-10	2017	This seemingly paradoxical result may be attributed to PGJ2 inhibiting some deubiquitinases (such as UCH-L1 but not USP14), thus triggering Ub-protein stabilization.	9-deoxy-delta-9-prostaglandin D2	55-59	ubiquitin C-terminal hydrolase L1	Rattus norvegicus	101-107
30236122-11	2018	In DA neurons, COX-2, L-PGDS, and 15-PGDH levels increased significantly in PGJ2-treated rats compared to controls, while DP2 receptor levels were unchanged.	9-deoxy-delta-9-prostaglandin D2	76-80	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	15-20
30236122-11	2018	In DA neurons, COX-2, L-PGDS, and 15-PGDH levels increased significantly in PGJ2-treated rats compared to controls, while DP2 receptor levels were unchanged.	9-deoxy-delta-9-prostaglandin D2	76-80	15-hydroxyprostaglandin dehydrogenase	Rattus norvegicus	34-41
30236122-12	2018	In microglia, DP2 receptors were basically non-detectable, while COX-2 and L-PGDS levels increased upon PGJ2-treatment, and 15-PGDH remained unchanged.	9-deoxy-delta-9-prostaglandin D2	104-108	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	65-70
30236122-16	2018	Moreover, prevention of most PGJ2-induced PD-like pathology with ibuprofen suggests a positive feedback mechanism between PGJ2 and COX-2 that could lead to chronic neuroinflammation.	9-deoxy-delta-9-prostaglandin D2	29-33	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	131-136
30236122-18	2018	Our findings support the notions that upregulation of COX-2 and L-PGDS may be important in the PGJ2 evoked PD-like pathology, and that neuronal DP2 receptor antagonists and L-PGDS inhibitors may be novel pharmacotherapeutics to relieve neuroinflammation-mediated neurodegeneration in PD, circumventing the adverse side effects of cyclooxygenase inhibitors.	9-deoxy-delta-9-prostaglandin D2	95-99	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	54-59
30193217-2	2018	Herein, we designed additional derivatives containing an exocyclic enone moiety that resembles the key structure of the natural PPAR-gamma ligand, 15-deoxy-Delta12, 14-prostaglandin J2 (15 d-PGJ2).	9-deoxy-delta-9-prostaglandin D2	190-195	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	128-138
30193217-3	2018	The exocyclic enone moiety of 15 d-PGJ2 is essential for covalent bonding with the Cys285 residue in the PPAR-gamma ligand-binding domain (LBD).	9-deoxy-delta-9-prostaglandin D2	35-39	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	105-115
29620161-10	2018	Finally, PPARgamma silencing markedly decreased the cleavage of the apoptotic markers, poly(ADP-ribose) polymerase 1 (PARP-1) and caspase-7, that usually occurs following b-15d-PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	177-181	peroxisome proliferator activated receptor gamma	Homo sapiens	9-18
29620161-10	2018	Finally, PPARgamma silencing markedly decreased the cleavage of the apoptotic markers, poly(ADP-ribose) polymerase 1 (PARP-1) and caspase-7, that usually occurs following b-15d-PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	177-181	poly(ADP-ribose) polymerase 1	Homo sapiens	87-116
29620161-10	2018	Finally, PPARgamma silencing markedly decreased the cleavage of the apoptotic markers, poly(ADP-ribose) polymerase 1 (PARP-1) and caspase-7, that usually occurs following b-15d-PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	177-181	caspase 7	Homo sapiens	130-139
31392591-5	2019	More interestingly, low concentrations of 15d-PGJ2 treatment facilitate the effects of PGE2 on the deposition of Abeta via TNF-alpha-dependent PS1/2 mechanisms.	9-deoxy-delta-9-prostaglandin D2	46-50	amyloid beta (A4) precursor protein	Mus musculus	113-118
31392591-5	2019	More interestingly, low concentrations of 15d-PGJ2 treatment facilitate the effects of PGE2 on the deposition of Abeta via TNF-alpha-dependent PS1/2 mechanisms.	9-deoxy-delta-9-prostaglandin D2	46-50	tumor necrosis factor	Mus musculus	123-132
31392591-5	2019	More interestingly, low concentrations of 15d-PGJ2 treatment facilitate the effects of PGE2 on the deposition of Abeta via TNF-alpha-dependent PS1/2 mechanisms.	9-deoxy-delta-9-prostaglandin D2	46-50	presenilin 1	Mus musculus	143-148
31392591-6	2019	In contrast, high concentrations of 15d-PGJ2 treatment inhibit the deposition of Abeta via suppressing the expression of TNF-alpha-dependent PS1/2.	9-deoxy-delta-9-prostaglandin D2	40-44	amyloid beta (A4) precursor protein	Mus musculus	81-86
31392591-6	2019	In contrast, high concentrations of 15d-PGJ2 treatment inhibit the deposition of Abeta via suppressing the expression of TNF-alpha-dependent PS1/2.	9-deoxy-delta-9-prostaglandin D2	40-44	tumor necrosis factor	Mus musculus	121-130
31392591-6	2019	In contrast, high concentrations of 15d-PGJ2 treatment inhibit the deposition of Abeta via suppressing the expression of TNF-alpha-dependent PS1/2.	9-deoxy-delta-9-prostaglandin D2	40-44	presenilin 2	Mus musculus	141-146
31467514-3	2019	Although many synthetic PPAR-gamma receptor agonists have been developed, as an endogenous product of PPAR-gamma receptors, 15d-PGJ2 has beneficial characteristics including rapid expression and the ability to contribute to a natural defence mechanism.	9-deoxy-delta-9-prostaglandin D2	127-132	peroxisome proliferator activated receptor gamma	Homo sapiens	24-34
30012349-4	2019	By acting as an 11-ketoprostaglandin reductase, AKR1C3 generates 11beta-PGF2alpha to activate the FP receptor and deprives peroxisome proliferator activator receptorgamma of its putative PGJ2 ligands.	9-deoxy-delta-9-prostaglandin D2	187-191	aldo-keto reductase family 1 member C3	Homo sapiens	48-54
30398845-9	2018	Calculated chemical properties as well as data from molecular orbital calculations, reactive molecular dynamics simulations, and intrinsic reaction coordinate modeling also supported the selectivity of 15d-PGJ2"s C9 toward PPARdelta"s Cys thiol.	9-deoxy-delta-9-prostaglandin D2	205-210	peroxisome proliferator activated receptor delta	Homo sapiens	223-232
30510777-2	2018	Although the metabolic products of COX-2, including prostaglandin (PG)E2, 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2), and PGF2alpha, have been reported to be effective in regulating the occurrence and development of OA by activating matrix metalloproteinases (MMPs), the roles of PGF2alpha in OA are largely overlooked.	9-deoxy-delta-9-prostaglandin D2	94-98	prostaglandin-endoperoxide synthase 2	Homo sapiens	35-40
30393164-1	2018	Prostaglandin (PG) D2 is relatively unstable and dehydrated non-enzymatically into PGJ2 derivatives, which are known to serve as pro-adipogenic factors by activating peroxisome proliferator-activated receptor (PPAR) gamma, a master regulator of adipogenesis.	9-deoxy-delta-9-prostaglandin D2	83-87	prostaglandin D2 synthase	Homo sapiens	0-21
30393164-1	2018	Prostaglandin (PG) D2 is relatively unstable and dehydrated non-enzymatically into PGJ2 derivatives, which are known to serve as pro-adipogenic factors by activating peroxisome proliferator-activated receptor (PPAR) gamma, a master regulator of adipogenesis.	9-deoxy-delta-9-prostaglandin D2	83-87	peroxisome proliferator activated receptor gamma	Homo sapiens	166-221
29966869-2	2018	The effectiveness of gallocyanines to inhibit DKK1/LRP6 interactions and Tau phosphorylation induced by prostaglandin J2 and DKK1 was elucidated by both experimental data and molecular docking simulations.	9-deoxy-delta-9-prostaglandin D2	104-120	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	46-50
29966869-2	2018	The effectiveness of gallocyanines to inhibit DKK1/LRP6 interactions and Tau phosphorylation induced by prostaglandin J2 and DKK1 was elucidated by both experimental data and molecular docking simulations.	9-deoxy-delta-9-prostaglandin D2	104-120	LDL receptor related protein 6	Homo sapiens	51-55
29966869-2	2018	The effectiveness of gallocyanines to inhibit DKK1/LRP6 interactions and Tau phosphorylation induced by prostaglandin J2 and DKK1 was elucidated by both experimental data and molecular docking simulations.	9-deoxy-delta-9-prostaglandin D2	104-120	microtubule associated protein tau	Homo sapiens	73-76
29622583-4	2018	Furthermore, in testing novel mutations with both prototypic endogenous (e.g., prostaglandin J2 [PGJ2]) and synthetic ligands (thiazolidinediones, tyrosine agonists), we observed that synthetic agonists selectively rescue function of some peroxisome proliferator-activated receptor-gamma (PPARgamma) mutants.	9-deoxy-delta-9-prostaglandin D2	79-95	peroxisome proliferator activated receptor gamma	Homo sapiens	239-287
29622583-4	2018	Furthermore, in testing novel mutations with both prototypic endogenous (e.g., prostaglandin J2 [PGJ2]) and synthetic ligands (thiazolidinediones, tyrosine agonists), we observed that synthetic agonists selectively rescue function of some peroxisome proliferator-activated receptor-gamma (PPARgamma) mutants.	9-deoxy-delta-9-prostaglandin D2	79-95	peroxisome proliferator activated receptor gamma	Homo sapiens	289-298
29622583-6	2018	Both PPARgamma mutants exhibit negligible constitutive or PGJ2-induced transcriptional activity but respond readily to synthetic agonists in vitro, with structural modeling providing a basis for such differential ligand-dependent responsiveness.	9-deoxy-delta-9-prostaglandin D2	58-62	peroxisome proliferator activated receptor gamma	Homo sapiens	5-14
26429394-5	2016	METHODS: In the current study we investigated the potential for AKR1C3 to regulate the availability of prostaglandin-derived ligands for PPARg mainly, prostaglandin J2 (PGJ2).	9-deoxy-delta-9-prostaglandin D2	151-167	aldo-keto reductase family 1 member C3	Homo sapiens	64-70
28115365-0	2017	Activation of PPARgamma by endogenous prostaglandin J2 mediates the antileukemic effect of selenium in murine leukemia.	9-deoxy-delta-9-prostaglandin D2	38-54	peroxisome proliferator activated receptor gamma	Mus musculus	14-23
26629858-3	2016	The current efforts resulted in the identification of potent DKK1 inhibitors which are able to inhibit prostaglandin J2-induced tau phosphorylation at serine 396.	9-deoxy-delta-9-prostaglandin D2	103-119	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	61-65
26629858-3	2016	The current efforts resulted in the identification of potent DKK1 inhibitors which are able to inhibit prostaglandin J2-induced tau phosphorylation at serine 396.	9-deoxy-delta-9-prostaglandin D2	103-119	microtubule associated protein tau	Homo sapiens	128-131
28454435-8	2017	By contrast, p120-catenin (p120-ctn) and beta-catenin levels staining accumulated in the region of the lamellipodium following 15d-PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	131-135	catenin delta 1	Homo sapiens	13-25
28454435-8	2017	By contrast, p120-catenin (p120-ctn) and beta-catenin levels staining accumulated in the region of the lamellipodium following 15d-PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	131-135	catenin delta 1	Homo sapiens	27-35
28454435-8	2017	By contrast, p120-catenin (p120-ctn) and beta-catenin levels staining accumulated in the region of the lamellipodium following 15d-PGJ2 treatment.	9-deoxy-delta-9-prostaglandin D2	131-135	catenin beta 1	Homo sapiens	41-53
27984728-4	2016	The upregulation of SGs by mutant KRAS is dependent on the production of the signaling lipid molecule 15-deoxy-delta 12,14 prostaglandin J2 (15-d-PGJ2) and confers cytoprotection against stress stimuli and chemotherapeutic agents.	9-deoxy-delta-9-prostaglandin D2	123-139	KRAS proto-oncogene, GTPase	Homo sapiens	34-38
27544994-5	2016	The effect of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) antagonist GW9662 on the regulation of MIF by 15 d-PGJ2 was observed.	9-deoxy-delta-9-prostaglandin D2	127-131	peroxisome proliferator activated receptor gamma	Mus musculus	14-62
27544994-5	2016	The effect of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) antagonist GW9662 on the regulation of MIF by 15 d-PGJ2 was observed.	9-deoxy-delta-9-prostaglandin D2	127-131	peroxisome proliferator activated receptor gamma	Mus musculus	64-74
27544994-5	2016	The effect of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) antagonist GW9662 on the regulation of MIF by 15 d-PGJ2 was observed.	9-deoxy-delta-9-prostaglandin D2	127-131	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	115-118
27544994-6	2016	The effects of 15 d-PGJ2 on the nuclear translocation of PPAR-gamma upon LPS challenge were detected via high content screening analysis.	9-deoxy-delta-9-prostaglandin D2	20-24	peroxisome proliferator activated receptor gamma	Mus musculus	57-67
27544994-12	2016	Conclusion 15 d-PGJ2 may down-regulate the MIF expression in J774A.1 in a PPAR-gamma-dependent manner.	9-deoxy-delta-9-prostaglandin D2	16-20	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	43-46
27544994-12	2016	Conclusion 15 d-PGJ2 may down-regulate the MIF expression in J774A.1 in a PPAR-gamma-dependent manner.	9-deoxy-delta-9-prostaglandin D2	16-20	peroxisome proliferator activated receptor gamma	Mus musculus	74-84
26801686-0	2016	Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death.	9-deoxy-delta-9-prostaglandin D2	98-102	AKT serine/threonine kinase 1	Homo sapiens	23-26
26801686-0	2016	Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death.	9-deoxy-delta-9-prostaglandin D2	98-102	NFE2 like bZIP transcription factor 2	Homo sapiens	27-31
26801686-0	2016	Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death.	9-deoxy-delta-9-prostaglandin D2	98-102	early growth response 1	Homo sapiens	32-36
26801686-0	2016	Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death.	9-deoxy-delta-9-prostaglandin D2	98-102	heme oxygenase 1	Homo sapiens	37-41
26801686-0	2016	Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death.	9-deoxy-delta-9-prostaglandin D2	98-102	glutamate-cysteine ligase catalytic subunit	Homo sapiens	42-46
26801686-3	2016	Therefore, the present study aimed to elucidate the impact of 15-deoxy-Delta(12,14)-PGJ2 (15d-PGJ2, a stable PGD2 degradation product) on cell death/cell survival pathways in p53-deficient MG-63 OS cells.	9-deoxy-delta-9-prostaglandin D2	83-88	tumor protein p53	Homo sapiens	175-178
26801686-7	2016	Activation of cell survival genes including HO-1 and GCLc inhibited 15d-PGJ2-induced cleavage of pro-caspase-3 and PARP.	9-deoxy-delta-9-prostaglandin D2	72-76	heme oxygenase 1	Homo sapiens	44-48
26801686-7	2016	Activation of cell survival genes including HO-1 and GCLc inhibited 15d-PGJ2-induced cleavage of pro-caspase-3 and PARP.	9-deoxy-delta-9-prostaglandin D2	72-76	glutamate-cysteine ligase catalytic subunit	Homo sapiens	53-57
26801686-7	2016	Activation of cell survival genes including HO-1 and GCLc inhibited 15d-PGJ2-induced cleavage of pro-caspase-3 and PARP.	9-deoxy-delta-9-prostaglandin D2	72-76	caspase 3	Homo sapiens	97-110
26801686-7	2016	Activation of cell survival genes including HO-1 and GCLc inhibited 15d-PGJ2-induced cleavage of pro-caspase-3 and PARP.	9-deoxy-delta-9-prostaglandin D2	72-76	collagen type XI alpha 2 chain	Homo sapiens	115-119
26801686-12	2016	Pharmacological or genetic interference of the pro-survival pathway, the p38 MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis, sensitizes MG-63 cells towards 15d-PGJ2-mediated apoptosis.	9-deoxy-delta-9-prostaglandin D2	147-151	mitogen-activated protein kinase 14	Homo sapiens	73-76
26801686-12	2016	Pharmacological or genetic interference of the pro-survival pathway, the p38 MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis, sensitizes MG-63 cells towards 15d-PGJ2-mediated apoptosis.	9-deoxy-delta-9-prostaglandin D2	147-151	AKT serine/threonine kinase 1	Homo sapiens	82-85
26801686-12	2016	Pharmacological or genetic interference of the pro-survival pathway, the p38 MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis, sensitizes MG-63 cells towards 15d-PGJ2-mediated apoptosis.	9-deoxy-delta-9-prostaglandin D2	147-151	NFE2 like bZIP transcription factor 2	Homo sapiens	86-90
26801686-12	2016	Pharmacological or genetic interference of the pro-survival pathway, the p38 MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis, sensitizes MG-63 cells towards 15d-PGJ2-mediated apoptosis.	9-deoxy-delta-9-prostaglandin D2	147-151	heme oxygenase 1	Homo sapiens	96-105
26429394-5	2016	METHODS: In the current study we investigated the potential for AKR1C3 to regulate the availability of prostaglandin-derived ligands for PPARg mainly, prostaglandin J2 (PGJ2).	9-deoxy-delta-9-prostaglandin D2	151-167	peroxisome proliferator activated receptor gamma	Homo sapiens	137-142
26429394-5	2016	METHODS: In the current study we investigated the potential for AKR1C3 to regulate the availability of prostaglandin-derived ligands for PPARg mainly, prostaglandin J2 (PGJ2).	9-deoxy-delta-9-prostaglandin D2	169-173	aldo-keto reductase family 1 member C3	Homo sapiens	64-70
26429394-5	2016	METHODS: In the current study we investigated the potential for AKR1C3 to regulate the availability of prostaglandin-derived ligands for PPARg mainly, prostaglandin J2 (PGJ2).	9-deoxy-delta-9-prostaglandin D2	169-173	peroxisome proliferator activated receptor gamma	Homo sapiens	137-142
25449421-3	2015	IGFBP-3 and the PPARgamma ligands, rosiglitazone or 15-deoxy-Delta(12,14)-prostaglandin J2, separately inhibited the proliferation of MCF-7, MDA-MB-231 and MDA-MB-468 breast cancer cells.	9-deoxy-delta-9-prostaglandin D2	74-90	insulin like growth factor binding protein 3	Homo sapiens	0-7
27872515-6	2016	Although the mRNA expression of ROR-gammat was profoundly reduced, FOXP3 was enhanced in draining lymph node cells from 15d-PGJ2-treated arthritic mice.	9-deoxy-delta-9-prostaglandin D2	124-128	forkhead box P3	Mus musculus	67-72
26115075-6	2015	In cultured cells, endogenous GPx2 expression and GPx2 promoter activity were enhanced by the anti-inflammatory mediators 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) and interleukin-22 (IL-22), while it was unaffected by classical proinflammatory cytokines like IL-1beta.	9-deoxy-delta-9-prostaglandin D2	143-160	glutathione peroxidase 2	Mus musculus	30-34
26115075-6	2015	In cultured cells, endogenous GPx2 expression and GPx2 promoter activity were enhanced by the anti-inflammatory mediators 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) and interleukin-22 (IL-22), while it was unaffected by classical proinflammatory cytokines like IL-1beta.	9-deoxy-delta-9-prostaglandin D2	143-160	glutathione peroxidase 2	Mus musculus	50-54
25618030-12	2015	The PPARgamma agonist PGJ2 enhances the 7K stimulatory effect on PPARgamma expression and activity but the antagonist GW9662 inhibits the 7K effect on the CD1d-expressing cells.	9-deoxy-delta-9-prostaglandin D2	22-26	peroxisome proliferator activated receptor gamma	Homo sapiens	4-13
25618030-12	2015	The PPARgamma agonist PGJ2 enhances the 7K stimulatory effect on PPARgamma expression and activity but the antagonist GW9662 inhibits the 7K effect on the CD1d-expressing cells.	9-deoxy-delta-9-prostaglandin D2	22-26	peroxisome proliferator activated receptor gamma	Homo sapiens	65-74
25449421-3	2015	IGFBP-3 and the PPARgamma ligands, rosiglitazone or 15-deoxy-Delta(12,14)-prostaglandin J2, separately inhibited the proliferation of MCF-7, MDA-MB-231 and MDA-MB-468 breast cancer cells.	9-deoxy-delta-9-prostaglandin D2	74-90	peroxisome proliferator activated receptor gamma	Homo sapiens	16-25
25001926-6	2014	Compared with the IFN-gamma plus TNF-alpha group (untreated with 15d-PGJ2), the CXCL9, CXCL10 and CXCL11 were depressed by 76.8%, 78.7% and 81.9% at mRNA level and 66.9%, 86.6% and 39.9% at protein level in 2.0 ng/mL 15d-PGJ2-treated HK-2 cells, respectively (P<0.05).	9-deoxy-delta-9-prostaglandin D2	68-73	interferon gamma	Homo sapiens	18-27
25171731-3	2015	We have demonstrated that bacterial signaling through Toll-like receptor (TLR) 4 induces 15-deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2) synthesis in intestinal MPhis by cyclooxygenase (Cox)-2 expression.	9-deoxy-delta-9-prostaglandin D2	131-136	toll like receptor 4	Homo sapiens	74-77
25677088-0	2015	Rac1 modification by an electrophilic 15-deoxy Delta(12,14)-prostaglandin J2 analog.	9-deoxy-delta-9-prostaglandin D2	60-76	Rac family small GTPase 1	Homo sapiens	0-4
25677088-13	2015	These results demonstrate for the first time that Rac1 is a target for 15d-PGJ2 in ECs, and suggest that Rac1 modification by electrophiles such as 15d-PGJ2 may alter redox signaling and EC function.	9-deoxy-delta-9-prostaglandin D2	74-79	Rac family small GTPase 1	Homo sapiens	50-54
25677088-13	2015	These results demonstrate for the first time that Rac1 is a target for 15d-PGJ2 in ECs, and suggest that Rac1 modification by electrophiles such as 15d-PGJ2 may alter redox signaling and EC function.	9-deoxy-delta-9-prostaglandin D2	74-79	Rac family small GTPase 1	Homo sapiens	105-109
24970746-3	2014	New therapeutic strategies that target factors downstream of COX-2, such as prostaglandin J2 (PGJ2), hold tremendous promise because they will not alter the homeostatic balance offered by COX-2 derived prostanoids.	9-deoxy-delta-9-prostaglandin D2	76-92	prostaglandin-endoperoxide synthase 2	Mus musculus	61-66
24970746-3	2014	New therapeutic strategies that target factors downstream of COX-2, such as prostaglandin J2 (PGJ2), hold tremendous promise because they will not alter the homeostatic balance offered by COX-2 derived prostanoids.	9-deoxy-delta-9-prostaglandin D2	94-98	prostaglandin-endoperoxide synthase 2	Mus musculus	61-66
24568186-3	2014	In the present work, we investigated the effects of HO-1 on the expression of p53 induced by 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) in human breast cancer (MCF-7) cells.	9-deoxy-delta-9-prostaglandin D2	115-131	heme oxygenase 1	Homo sapiens	52-56
24568186-3	2014	In the present work, we investigated the effects of HO-1 on the expression of p53 induced by 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) in human breast cancer (MCF-7) cells.	9-deoxy-delta-9-prostaglandin D2	115-131	tumor protein p53	Homo sapiens	78-81
25072357-3	2014	In this manuscript, we report that the 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2), peroxisome proliferator-activated receptor gamma (PPARgamma) activator leads to the downregulation of the cancer-associated expression of B7-H1 in response to interferon-gamma (IFN-gamma) and the associated signaling cascades.	9-deoxy-delta-9-prostaglandin D2	61-77	peroxisome proliferator activated receptor gamma	Mus musculus	90-138
25072357-3	2014	In this manuscript, we report that the 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2), peroxisome proliferator-activated receptor gamma (PPARgamma) activator leads to the downregulation of the cancer-associated expression of B7-H1 in response to interferon-gamma (IFN-gamma) and the associated signaling cascades.	9-deoxy-delta-9-prostaglandin D2	61-77	peroxisome proliferator activated receptor gamma	Mus musculus	140-149
25072357-3	2014	In this manuscript, we report that the 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2), peroxisome proliferator-activated receptor gamma (PPARgamma) activator leads to the downregulation of the cancer-associated expression of B7-H1 in response to interferon-gamma (IFN-gamma) and the associated signaling cascades.	9-deoxy-delta-9-prostaglandin D2	61-77	CD274 antigen	Mus musculus	228-233
25072357-3	2014	In this manuscript, we report that the 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2), peroxisome proliferator-activated receptor gamma (PPARgamma) activator leads to the downregulation of the cancer-associated expression of B7-H1 in response to interferon-gamma (IFN-gamma) and the associated signaling cascades.	9-deoxy-delta-9-prostaglandin D2	61-77	interferon gamma	Mus musculus	249-265
25072357-3	2014	In this manuscript, we report that the 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2), peroxisome proliferator-activated receptor gamma (PPARgamma) activator leads to the downregulation of the cancer-associated expression of B7-H1 in response to interferon-gamma (IFN-gamma) and the associated signaling cascades.	9-deoxy-delta-9-prostaglandin D2	61-77	interferon gamma	Mus musculus	267-276
24680891-1	2014	A ligand of peroxisome proliferator-activated receptor gamma (PPARgamma), 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) induces apoptosis in various cells.	9-deoxy-delta-9-prostaglandin D2	96-112	peroxisome proliferator-activated receptor gamma	Oryctolagus cuniculus	12-60
24680891-1	2014	A ligand of peroxisome proliferator-activated receptor gamma (PPARgamma), 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) induces apoptosis in various cells.	9-deoxy-delta-9-prostaglandin D2	96-112	peroxisome proliferator-activated receptor gamma	Oryctolagus cuniculus	62-71
24680891-1	2014	A ligand of peroxisome proliferator-activated receptor gamma (PPARgamma), 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) induces apoptosis in various cells.	9-deoxy-delta-9-prostaglandin D2	118-122	peroxisome proliferator-activated receptor gamma	Oryctolagus cuniculus	12-60
24680891-1	2014	A ligand of peroxisome proliferator-activated receptor gamma (PPARgamma), 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) induces apoptosis in various cells.	9-deoxy-delta-9-prostaglandin D2	118-122	peroxisome proliferator-activated receptor gamma	Oryctolagus cuniculus	62-71
25140003-9	2014	The ability of 15d-PGJ2-G to activate the canonical nuclear factor erythroid 2-related factor (Nrf2) signaling pathway used by 15d-PGJ2 was assessed, and these studies revealed for the first time that 15d-PGJ2 and 15d-PGJ2-G similarly activated Nrf2 signaling as well as transcription of target genes of this pathway.	9-deoxy-delta-9-prostaglandin D2	19-23	NFE2 like bZIP transcription factor 2	Homo sapiens	52-93
25140003-9	2014	The ability of 15d-PGJ2-G to activate the canonical nuclear factor erythroid 2-related factor (Nrf2) signaling pathway used by 15d-PGJ2 was assessed, and these studies revealed for the first time that 15d-PGJ2 and 15d-PGJ2-G similarly activated Nrf2 signaling as well as transcription of target genes of this pathway.	9-deoxy-delta-9-prostaglandin D2	19-23	NFE2 like bZIP transcription factor 2	Homo sapiens	95-99
25140003-9	2014	The ability of 15d-PGJ2-G to activate the canonical nuclear factor erythroid 2-related factor (Nrf2) signaling pathway used by 15d-PGJ2 was assessed, and these studies revealed for the first time that 15d-PGJ2 and 15d-PGJ2-G similarly activated Nrf2 signaling as well as transcription of target genes of this pathway.	9-deoxy-delta-9-prostaglandin D2	19-23	NFE2 like bZIP transcription factor 2	Homo sapiens	245-249
25140003-9	2014	The ability of 15d-PGJ2-G to activate the canonical nuclear factor erythroid 2-related factor (Nrf2) signaling pathway used by 15d-PGJ2 was assessed, and these studies revealed for the first time that 15d-PGJ2 and 15d-PGJ2-G similarly activated Nrf2 signaling as well as transcription of target genes of this pathway.	9-deoxy-delta-9-prostaglandin D2	18-23	NFE2 like bZIP transcription factor 2	Homo sapiens	52-93
25140003-9	2014	The ability of 15d-PGJ2-G to activate the canonical nuclear factor erythroid 2-related factor (Nrf2) signaling pathway used by 15d-PGJ2 was assessed, and these studies revealed for the first time that 15d-PGJ2 and 15d-PGJ2-G similarly activated Nrf2 signaling as well as transcription of target genes of this pathway.	9-deoxy-delta-9-prostaglandin D2	18-23	NFE2 like bZIP transcription factor 2	Homo sapiens	95-99
25140003-9	2014	The ability of 15d-PGJ2-G to activate the canonical nuclear factor erythroid 2-related factor (Nrf2) signaling pathway used by 15d-PGJ2 was assessed, and these studies revealed for the first time that 15d-PGJ2 and 15d-PGJ2-G similarly activated Nrf2 signaling as well as transcription of target genes of this pathway.	9-deoxy-delta-9-prostaglandin D2	18-23	NFE2 like bZIP transcription factor 2	Homo sapiens	245-249
25140003-9	2014	The ability of 15d-PGJ2-G to activate the canonical nuclear factor erythroid 2-related factor (Nrf2) signaling pathway used by 15d-PGJ2 was assessed, and these studies revealed for the first time that 15d-PGJ2 and 15d-PGJ2-G similarly activated Nrf2 signaling as well as transcription of target genes of this pathway.	9-deoxy-delta-9-prostaglandin D2	131-135	NFE2 like bZIP transcription factor 2	Homo sapiens	52-93
25140003-9	2014	The ability of 15d-PGJ2-G to activate the canonical nuclear factor erythroid 2-related factor (Nrf2) signaling pathway used by 15d-PGJ2 was assessed, and these studies revealed for the first time that 15d-PGJ2 and 15d-PGJ2-G similarly activated Nrf2 signaling as well as transcription of target genes of this pathway.	9-deoxy-delta-9-prostaglandin D2	131-135	NFE2 like bZIP transcription factor 2	Homo sapiens	95-99
26461395-9	2014	In addition, the treatment of PC12 cells with biotinylated 15d-PGJ2 resulted in the formation of a 15d-PGJ2-TRPV1 adduct, indicating that 15d-PGJ2 directly modified the TRPV1 in the cells.	9-deoxy-delta-9-prostaglandin D2	63-67	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	108-113
26461395-9	2014	In addition, the treatment of PC12 cells with biotinylated 15d-PGJ2 resulted in the formation of a 15d-PGJ2-TRPV1 adduct, indicating that 15d-PGJ2 directly modified the TRPV1 in the cells.	9-deoxy-delta-9-prostaglandin D2	63-67	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	169-174
25371531-5	2014	A natural PPARgamma agonist, PGJ2, reduced P4 release on days 14-16 or days 10-12 of pregnancy, respectively.	9-deoxy-delta-9-prostaglandin D2	29-33	peroxisome proliferator activated receptor gamma	Homo sapiens	10-19
25773924-4	2014	In the present study, we demonstrate that 15-deoxy-Delta(12,14)-prostaglandin J2 (15 d-PGJ2), one of the terminal products of cyclooxygenase-2, updregulates the expression and the activity of 15-PGDH in human breast cancer MDA-MB-231 cells.	9-deoxy-delta-9-prostaglandin D2	87-91	prostaglandin-endoperoxide synthase 2	Homo sapiens	126-142
25773924-4	2014	In the present study, we demonstrate that 15-deoxy-Delta(12,14)-prostaglandin J2 (15 d-PGJ2), one of the terminal products of cyclooxygenase-2, updregulates the expression and the activity of 15-PGDH in human breast cancer MDA-MB-231 cells.	9-deoxy-delta-9-prostaglandin D2	87-91	carbonyl reductase 1	Homo sapiens	192-199
25773924-6	2014	15 d-PGJ2 induced phosphorylation of Elk-1, one of Ets transcription factor family members, in the nucleus.	9-deoxy-delta-9-prostaglandin D2	5-9	ETS transcription factor ELK1	Homo sapiens	37-42
25773924-8	2014	Furthermore, 15 d-PGJ2-mediated activation of Elk-1 was found to be dependent on activation of extracellular-signal related kinase (ERK) 1/2.	9-deoxy-delta-9-prostaglandin D2	18-22	ETS transcription factor ELK1	Homo sapiens	46-51
25773924-8	2014	Furthermore, 15 d-PGJ2-mediated activation of Elk-1 was found to be dependent on activation of extracellular-signal related kinase (ERK) 1/2.	9-deoxy-delta-9-prostaglandin D2	18-22	mitogen-activated protein kinase 3	Homo sapiens	95-140
25773924-9	2014	Treatment of U0126, a pharmacological inhibitor of MEK1/2-ERK, abolished phosphorylation and DNA binding of Elk-1 as well as 15-PGDH induction in 15 d-PGJ2-treated MDA-MB-231 cells.	9-deoxy-delta-9-prostaglandin D2	151-155	mitogen-activated protein kinase kinase 1	Homo sapiens	51-57
25773924-9	2014	Treatment of U0126, a pharmacological inhibitor of MEK1/2-ERK, abolished phosphorylation and DNA binding of Elk-1 as well as 15-PGDH induction in 15 d-PGJ2-treated MDA-MB-231 cells.	9-deoxy-delta-9-prostaglandin D2	151-155	mitogen-activated protein kinase 1	Homo sapiens	58-61
25773924-9	2014	Treatment of U0126, a pharmacological inhibitor of MEK1/2-ERK, abolished phosphorylation and DNA binding of Elk-1 as well as 15-PGDH induction in 15 d-PGJ2-treated MDA-MB-231 cells.	9-deoxy-delta-9-prostaglandin D2	151-155	ETS transcription factor ELK1	Homo sapiens	108-113
25773924-9	2014	Treatment of U0126, a pharmacological inhibitor of MEK1/2-ERK, abolished phosphorylation and DNA binding of Elk-1 as well as 15-PGDH induction in 15 d-PGJ2-treated MDA-MB-231 cells.	9-deoxy-delta-9-prostaglandin D2	151-155	carbonyl reductase 1	Homo sapiens	125-132
25773924-10	2014	Moreover, 15 d-PGJ2 generated reactive oxygen species (ROS), which contribute to the expression of 15-PGDH as well as phosphorylation of ERK1/2 and Elk-1.	9-deoxy-delta-9-prostaglandin D2	15-19	carbonyl reductase 1	Homo sapiens	99-106
25773924-10	2014	Moreover, 15 d-PGJ2 generated reactive oxygen species (ROS), which contribute to the expression of 15-PGDH as well as phosphorylation of ERK1/2 and Elk-1.	9-deoxy-delta-9-prostaglandin D2	15-19	mitogen-activated protein kinase 3	Homo sapiens	137-143
25773924-10	2014	Moreover, 15 d-PGJ2 generated reactive oxygen species (ROS), which contribute to the expression of 15-PGDH as well as phosphorylation of ERK1/2 and Elk-1.	9-deoxy-delta-9-prostaglandin D2	15-19	ETS transcription factor ELK1	Homo sapiens	148-153
25773924-11	2014	15 d-PGJ2 inhibited the migration of MDA-MB-231 cells, which was attenuated by transient transfection with 15-PGDH siRNA.	9-deoxy-delta-9-prostaglandin D2	5-9	carbonyl reductase 1	Homo sapiens	107-114
25773924-12	2014	Taken together, these findings suggest that 15 d-PGJ2 induces the expression of 15-PGDH through ROS-mediated activation of ERK1/2 and subsequently Elk-1 in the MDA-MB-231 cells, which may contribute to tumor suppressive activity of this cyclopentenone prostaglandin.	9-deoxy-delta-9-prostaglandin D2	48-53	carbonyl reductase 1	Homo sapiens	80-87
25773924-12	2014	Taken together, these findings suggest that 15 d-PGJ2 induces the expression of 15-PGDH through ROS-mediated activation of ERK1/2 and subsequently Elk-1 in the MDA-MB-231 cells, which may contribute to tumor suppressive activity of this cyclopentenone prostaglandin.	9-deoxy-delta-9-prostaglandin D2	48-53	mitogen-activated protein kinase 3	Homo sapiens	123-129
25773924-12	2014	Taken together, these findings suggest that 15 d-PGJ2 induces the expression of 15-PGDH through ROS-mediated activation of ERK1/2 and subsequently Elk-1 in the MDA-MB-231 cells, which may contribute to tumor suppressive activity of this cyclopentenone prostaglandin.	9-deoxy-delta-9-prostaglandin D2	48-53	ETS transcription factor ELK1	Homo sapiens	147-152
25001926-6	2014	Compared with the IFN-gamma plus TNF-alpha group (untreated with 15d-PGJ2), the CXCL9, CXCL10 and CXCL11 were depressed by 76.8%, 78.7% and 81.9% at mRNA level and 66.9%, 86.6% and 39.9% at protein level in 2.0 ng/mL 15d-PGJ2-treated HK-2 cells, respectively (P<0.05).	9-deoxy-delta-9-prostaglandin D2	68-73	tumor necrosis factor	Homo sapiens	33-42
25001926-6	2014	Compared with the IFN-gamma plus TNF-alpha group (untreated with 15d-PGJ2), the CXCL9, CXCL10 and CXCL11 were depressed by 76.8%, 78.7% and 81.9% at mRNA level and 66.9%, 86.6% and 39.9% at protein level in 2.0 ng/mL 15d-PGJ2-treated HK-2 cells, respectively (P<0.05).	9-deoxy-delta-9-prostaglandin D2	68-73	C-X-C motif chemokine ligand 9	Homo sapiens	80-85
24289988-0	2014	PGJ2 restores RA sensitivity in melanoma cells by decreasing PRAME and EZH2.	9-deoxy-delta-9-prostaglandin D2	0-4	PRAME nuclear receptor transcriptional regulator	Homo sapiens	61-66
24718259-5	2014	MT-III caused a marked release of PGE2, PGD2, PGJ2, IL-1beta and IL-10 and increased the number of LDs in WT macrophages.	9-deoxy-delta-9-prostaglandin D2	46-50	metallothionein 3	Homo sapiens	0-6
24718259-7	2014	In MyD88-/- macrophages, MT-III-induced release of PGE2, IL-1beta and IL-10 was abrogated, but release of PGD2 and PGJ2 was maintained.	9-deoxy-delta-9-prostaglandin D2	115-119	metallothionein 3	Homo sapiens	25-31
24612634-7	2014	In vitro, both rosiglitazone and 15 d-PGJ2 inhibited CS-induced inflammation through the TLR4 signaling pathway.	9-deoxy-delta-9-prostaglandin D2	37-42	toll-like receptor 4	Rattus norvegicus	89-93
24289988-0	2014	PGJ2 restores RA sensitivity in melanoma cells by decreasing PRAME and EZH2.	9-deoxy-delta-9-prostaglandin D2	0-4	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	71-75
23688403-14	2013	CONCLUSIONS: Antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine, and amorolfine may suppress poly I:C plus IL-4-induced production of TSLP by inhibiting NF-kappaB via increasing 15d-PGJ2 production in keratinocytes.	9-deoxy-delta-9-prostaglandin D2	210-214	interleukin 4	Homo sapiens	135-139
24287039-7	2013	PPARgamma agonist (PGJ2) and antagonist (T0070907) enhanced PGFS mRNA abundance in the endometrium on days 10-12 and 14-16 of pregnancy, respectively.	9-deoxy-delta-9-prostaglandin D2	19-23	peroxisome proliferator activated receptor gamma	Homo sapiens	0-9
24287039-7	2013	PPARgamma agonist (PGJ2) and antagonist (T0070907) enhanced PGFS mRNA abundance in the endometrium on days 10-12 and 14-16 of pregnancy, respectively.	9-deoxy-delta-9-prostaglandin D2	19-23	aldo-keto reductase family 1 member C3	Homo sapiens	60-64
23817787-9	2013	The results suggest that the inducible COX-2 can contribute to the endogenous synthesis of PGJ2 derivatives acting as autocrine mediators to simulate adipogenesis during the maturation phase by way of compensation for the suppressed expression of the constitutive COX-1.	9-deoxy-delta-9-prostaglandin D2	91-95	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	39-44
23817787-9	2013	The results suggest that the inducible COX-2 can contribute to the endogenous synthesis of PGJ2 derivatives acting as autocrine mediators to simulate adipogenesis during the maturation phase by way of compensation for the suppressed expression of the constitutive COX-1.	9-deoxy-delta-9-prostaglandin D2	91-95	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	264-269
24471457-14	2014	The antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine and amorolfine may suppress the M. restricta-induced production of CXCL10 by inhibiting STAT1 through an increase in 15d-PGJ2 production in keratinocytes.	9-deoxy-delta-9-prostaglandin D2	204-208	C-X-C motif chemokine ligand 10	Homo sapiens	150-156
24471457-14	2014	The antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine and amorolfine may suppress the M. restricta-induced production of CXCL10 by inhibiting STAT1 through an increase in 15d-PGJ2 production in keratinocytes.	9-deoxy-delta-9-prostaglandin D2	204-208	signal transducer and activator of transcription 1	Homo sapiens	171-176
23688403-14	2013	CONCLUSIONS: Antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine, and amorolfine may suppress poly I:C plus IL-4-induced production of TSLP by inhibiting NF-kappaB via increasing 15d-PGJ2 production in keratinocytes.	9-deoxy-delta-9-prostaglandin D2	210-214	thymic stromal lymphopoietin	Homo sapiens	162-166
24377602-2	2013	An endogenous ligand of PPARgamma, 15-deoxy-Delta12,14 prostaglandin J2 (PGJ2), is emerging as a potent anticancer agent but the exact mechanism has not been fully elucidated, especially in breast cancer.	9-deoxy-delta-9-prostaglandin D2	55-71	peroxisome proliferator activated receptor gamma	Homo sapiens	24-33
23707573-7	2013	Moreover, molecular docking combined with molecular dynamics simulation was applied to develop the possible model of 15d-PGJ2 binding to hFXRalpha ligand binding domain (LBD) at atomic level, and the responsible residues for 15d-PGJ2/hFXRalpha-LBD interaction were thereby determined, which were further confirmed by SPR assays against hFXRalpha-LBD site-directed mutations.	9-deoxy-delta-9-prostaglandin D2	120-125	sepiapterin reductase	Homo sapiens	317-320
23365414-5	2013	In CL cultured in vitro, the PPARgamma agonist (15-deoxy delta12,14 prostaglandin J2 [15d-PGJ2], 200 nM) increased and the antagonist (T0070907, 50 nM) decreased progesterone secretion at early and midluteal stages, whereas 15d-PGJ2 reduced and T0070907 increased PGF2alpha at the same stages.	9-deoxy-delta-9-prostaglandin D2	68-84	peroxisome proliferator-activated receptor gamma	Oryctolagus cuniculus	29-38
24377602-2	2013	An endogenous ligand of PPARgamma, 15-deoxy-Delta12,14 prostaglandin J2 (PGJ2), is emerging as a potent anticancer agent but the exact mechanism has not been fully elucidated, especially in breast cancer.	9-deoxy-delta-9-prostaglandin D2	73-77	peroxisome proliferator activated receptor gamma	Homo sapiens	24-33
24377602-3	2013	The present study compared the anticancer effects of PGJ2 on estrogen receptor alpha (ERalpha)-positive (MCF-7) and ERalpha-negative (MDA-MB-231) human breast cancer cells.	9-deoxy-delta-9-prostaglandin D2	53-57	estrogen receptor 1	Homo sapiens	61-84
22138303-9	2012	These results indicate that Cox-2 induces clusterin in a 15d-PGJ(2)-dependent manner, and via activation of HSF-1 and PPARgamma.	9-deoxy-delta-9-prostaglandin D2	61-67	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	28-33
24377602-4	2013	Based on the reported signalling cross-talk between PPARgamma and ERalpha, the effect of the ERalpha ligand, 17beta-estradiol (E2) on the anticancer activities of PGJ2 in both types of cells was also explored.	9-deoxy-delta-9-prostaglandin D2	163-167	peroxisome proliferator activated receptor gamma	Homo sapiens	52-61
24377602-4	2013	Based on the reported signalling cross-talk between PPARgamma and ERalpha, the effect of the ERalpha ligand, 17beta-estradiol (E2) on the anticancer activities of PGJ2 in both types of cells was also explored.	9-deoxy-delta-9-prostaglandin D2	163-167	estrogen receptor 1	Homo sapiens	93-100
24377602-9	2013	It can be concluded that E2 enhances PPARgamma-independent anticancer effects of PGJ2 in the presence of its receptor.	9-deoxy-delta-9-prostaglandin D2	81-85	peroxisome proliferator activated receptor gamma	Homo sapiens	37-46
23088980-6	2012	RESULTS: In MB49 cells bacillus Calmette-Guerin and 15-d-PGJ2 induced PPARg expression, nuclear translocation and transcriptional activity.	9-deoxy-delta-9-prostaglandin D2	56-61	peroxisome proliferator activated receptor gamma	Homo sapiens	70-75
22561694-0	2012	Prostaglandin J2 series induces the gene expression of monocyte chemoattractant protein-1 during the maturation phase of cultured adipocytes.	9-deoxy-delta-9-prostaglandin D2	0-16	C-C motif chemokine ligand 2	Homo sapiens	55-89
22245093-4	2012	Here, we tested the hypothesis that 15 d-PGJ(2) modulates Mn-induced activation of astrocytic intracellular signaling, including NF-kappaB and nuclear factor erythroid 2-related factor (Nrf2), a master regulator of antioxidant transcriptional responses.	9-deoxy-delta-9-prostaglandin D2	41-47	nuclear factor kappa B subunit 1	Homo sapiens	129-138
22245093-4	2012	Here, we tested the hypothesis that 15 d-PGJ(2) modulates Mn-induced activation of astrocytic intracellular signaling, including NF-kappaB and nuclear factor erythroid 2-related factor (Nrf2), a master regulator of antioxidant transcriptional responses.	9-deoxy-delta-9-prostaglandin D2	41-47	NFE2 like bZIP transcription factor 2	Homo sapiens	143-184
22245093-11	2012	Nevertheless, cotreatment of whole-cell lysates with both Mn and 15 d-PGJ(2) partially suppressed (p<0.01) the 15 d-PGJ(2)-induced increase in astrocytic Nrf2 protein expression.	9-deoxy-delta-9-prostaglandin D2	70-76	NFE2 like bZIP transcription factor 2	Homo sapiens	154-158
22138303-9	2012	These results indicate that Cox-2 induces clusterin in a 15d-PGJ(2)-dependent manner, and via activation of HSF-1 and PPARgamma.	9-deoxy-delta-9-prostaglandin D2	61-67	clusterin	Rattus norvegicus	42-51
22701540-9	2012	Activation of TRPA1 by allyl isothiocyanate (AITC), hydrogen peroxide (H2O2), 4-hydroxynonenal (4-HNE), and cyclopentenone prostaglandins (PGJ2) and a novel agonist methylglyoxal (MG) induces membrane current, depolarization, and Ca2+ influx leading to generation of action potentials in a pancreatic beta cell line and primary cultured pancreatic beta cells.	9-deoxy-delta-9-prostaglandin D2	139-143	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	14-19
22003398-0	2011	15-Deoxy-Delta12,14 prostaglandin J2 reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice.	9-deoxy-delta-9-prostaglandin D2	20-36	apolipoprotein E	Mus musculus	89-105
21376806-10	2011	The findings in this study demonstrate that the peroxisome proliferator-activated receptor-gamma agonists 15-deoxy-Delta12,15 prostaglandin J2 and pioglitazone protect cultured granule cells and microglia from the toxic effects of ethanol.	9-deoxy-delta-9-prostaglandin D2	126-142	peroxisome proliferator activated receptor gamma	Mus musculus	48-96
21728338-0	2011	Multidrug resistance-associated protein 1 mediates 15-deoxy-Delta(12,14)-prostaglandin J2-induced expression of glutamate cysteine ligase expression via Nrf2 signaling in human breast cancer cells.	9-deoxy-delta-9-prostaglandin D2	73-89	ATP binding cassette subfamily C member 1	Homo sapiens	0-41
21728338-0	2011	Multidrug resistance-associated protein 1 mediates 15-deoxy-Delta(12,14)-prostaglandin J2-induced expression of glutamate cysteine ligase expression via Nrf2 signaling in human breast cancer cells.	9-deoxy-delta-9-prostaglandin D2	73-89	NFE2 like bZIP transcription factor 2	Homo sapiens	153-157
20221637-5	2011	The PPARgamma agonists ciglitazone and PGJ(2) were the most effective inducers with up to ninefold and threefold increases in VEGF mRNA in SW480 and HT29 cultures, respectively.	9-deoxy-delta-9-prostaglandin D2	39-45	peroxisome proliferator activated receptor gamma	Homo sapiens	4-13
20221637-5	2011	The PPARgamma agonists ciglitazone and PGJ(2) were the most effective inducers with up to ninefold and threefold increases in VEGF mRNA in SW480 and HT29 cultures, respectively.	9-deoxy-delta-9-prostaglandin D2	39-45	vascular endothelial growth factor A	Homo sapiens	126-130
22003398-1	2011	AIM: 15-deoxy-Delta12,14 prostaglandin J2 (15d-PGJ2) is a ligand of peroxisome proliferator-activated receptor gamma (PPARgamma) having diverse effects such as the differentiation of adipocytes and atherosclerotic lesion formation.	9-deoxy-delta-9-prostaglandin D2	25-41	peroxisome proliferator activated receptor gamma	Mus musculus	68-116
22003398-1	2011	AIM: 15-deoxy-Delta12,14 prostaglandin J2 (15d-PGJ2) is a ligand of peroxisome proliferator-activated receptor gamma (PPARgamma) having diverse effects such as the differentiation of adipocytes and atherosclerotic lesion formation.	9-deoxy-delta-9-prostaglandin D2	25-41	peroxisome proliferator activated receptor gamma	Mus musculus	118-127
22003398-1	2011	AIM: 15-deoxy-Delta12,14 prostaglandin J2 (15d-PGJ2) is a ligand of peroxisome proliferator-activated receptor gamma (PPARgamma) having diverse effects such as the differentiation of adipocytes and atherosclerotic lesion formation.	9-deoxy-delta-9-prostaglandin D2	47-51	peroxisome proliferator activated receptor gamma	Mus musculus	68-116
22003398-1	2011	AIM: 15-deoxy-Delta12,14 prostaglandin J2 (15d-PGJ2) is a ligand of peroxisome proliferator-activated receptor gamma (PPARgamma) having diverse effects such as the differentiation of adipocytes and atherosclerotic lesion formation.	9-deoxy-delta-9-prostaglandin D2	47-51	peroxisome proliferator activated receptor gamma	Mus musculus	118-127
22003398-7	2011	Immunohistochemical and real-time PCR analyses showed that the expression of MCP-1, TNF-alpha, and MMP-9 in atherosclerotic lesions was significantly decreased in 15d-PGJ2 treated mice.	9-deoxy-delta-9-prostaglandin D2	167-171	mast cell protease 1	Mus musculus	77-82
22003398-7	2011	Immunohistochemical and real-time PCR analyses showed that the expression of MCP-1, TNF-alpha, and MMP-9 in atherosclerotic lesions was significantly decreased in 15d-PGJ2 treated mice.	9-deoxy-delta-9-prostaglandin D2	167-171	tumor necrosis factor	Mus musculus	84-93
22003398-7	2011	Immunohistochemical and real-time PCR analyses showed that the expression of MCP-1, TNF-alpha, and MMP-9 in atherosclerotic lesions was significantly decreased in 15d-PGJ2 treated mice.	9-deoxy-delta-9-prostaglandin D2	167-171	matrix metallopeptidase 9	Mus musculus	99-104
20307494-0	2010	Inhibition of mitochondrial division through covalent modification of Drp1 protein by 15 deoxy-Delta(12,14)-prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	108-124	collapsin response mediator protein 1	Homo sapiens	70-74
20919899-6	2010	RESULTS: The GAG concentrations of cartilage expiants cultured in IL-1beta (100 ng/mL) with 2 concentrations of PGJ2 were significantly higher than those in all other groups, whereas media GAG concentrations were significantly lower in the high-concentration PGJ2-treated groups, compared with all other groups.	9-deoxy-delta-9-prostaglandin D2	112-116	interleukin 1 beta	Canis lupus familiaris	66-74
20919899-9	2010	CONCLUSIONS AND CLINICAL RELEVANCE: PGJ2, an endogenous PPARgamma agonist, may have anti-inflammatory and chondroprotective effects in an osteosteoarthritic joint environment.	9-deoxy-delta-9-prostaglandin D2	36-40	peroxisome proliferator activated receptor gamma	Canis lupus familiaris	56-65
20862655-2	2010	Among peroxisome proliferators, fibrate derivatives are considered specific ligands for PPARalpha, whereas eicosanoids, such as PGJ2, for PPARgamma.	9-deoxy-delta-9-prostaglandin D2	128-132	peroxisome proliferator activated receptor gamma	Homo sapiens	138-147
20678484-1	2010	We showed earlier that 15 deoxy Delta(12,14) prostaglandin J2 (15d-PGJ2) inactivates Drp1 and induces mitochondrial fusion [1].	9-deoxy-delta-9-prostaglandin D2	45-61	collapsin response mediator protein 1	Homo sapiens	85-89
21085594-6	2010	This procedure, PROP, demonstrated in vivo oxidation of p38 in response to hydrogen peroxide and also to the natural inflammatory lipid prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	136-152	mitogen-activated protein kinase 14	Homo sapiens	56-59
20224069-10	2010	15 Deoxy-Delta(12,14)-prostaglandin J(2) administration significantly reduced hyperoxia-induced lung inflammation and edema in Nrf2(+/+), but not in Nrf2(-/-) mice.	9-deoxy-delta-9-prostaglandin D2	22-40	nuclear factor, erythroid derived 2, like 2	Mus musculus	127-131
19262292-6	2009	The lung maturation effect of PPARgamma agonists was also confirmed by another PPARgamma agonist, the naturally occurring PPARgamma ligand prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	139-155	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	30-39
20020468-8	2010	In addition, endogenous PPARgamma ligand, 15-deoxy-Delta(12,14)-prostaglandin-J2 (15d-PGJ2) markedly increased both mRNA and protein levels of HO-1 in osteoblasts via PI3K-Akt and MAPK pathways.	9-deoxy-delta-9-prostaglandin D2	63-80	peroxisome proliferator activated receptor gamma	Homo sapiens	24-33
20020468-8	2010	In addition, endogenous PPARgamma ligand, 15-deoxy-Delta(12,14)-prostaglandin-J2 (15d-PGJ2) markedly increased both mRNA and protein levels of HO-1 in osteoblasts via PI3K-Akt and MAPK pathways.	9-deoxy-delta-9-prostaglandin D2	63-80	heme oxygenase 1	Homo sapiens	143-147
20020468-8	2010	In addition, endogenous PPARgamma ligand, 15-deoxy-Delta(12,14)-prostaglandin-J2 (15d-PGJ2) markedly increased both mRNA and protein levels of HO-1 in osteoblasts via PI3K-Akt and MAPK pathways.	9-deoxy-delta-9-prostaglandin D2	63-80	AKT serine/threonine kinase 1	Homo sapiens	172-175
20036328-8	2010	MCF-7-AKR1C3 cells also reduced PGD(2), limiting its dehydration to form PGJ(2) products.	9-deoxy-delta-9-prostaglandin D2	73-79	aldo-keto reductase family 1 member C3	Homo sapiens	6-12
19630993-12	2009	PGJ2 also triggered formation of aggregates immunoreactive for ubiquitin and alpha-synuclein in the spared dopaminergic neurons.	9-deoxy-delta-9-prostaglandin D2	0-4	synuclein, alpha	Mus musculus	77-92
19457109-0	2009	Proteasome-caspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells.	9-deoxy-delta-9-prostaglandin D2	74-90	microtubule associated protein tau	Homo sapiens	49-52
19457109-4	2009	We show that prostaglandin (PG) J2, an endogenous product of inflammation, induces caspase-mediated cleavage of tau, generating Deltatau, an aggregation prone form known to seed tau aggregation prior to neurofibrillary tangle formation.	9-deoxy-delta-9-prostaglandin D2	13-34	microtubule associated protein tau	Homo sapiens	112-115
19457109-4	2009	We show that prostaglandin (PG) J2, an endogenous product of inflammation, induces caspase-mediated cleavage of tau, generating Deltatau, an aggregation prone form known to seed tau aggregation prior to neurofibrillary tangle formation.	9-deoxy-delta-9-prostaglandin D2	13-34	microtubule associated protein tau	Homo sapiens	133-136
19457109-8	2009	Upon PGJ2-treatment tau accumulated in a large perinuclear aggregate.	9-deoxy-delta-9-prostaglandin D2	5-9	microtubule associated protein tau	Homo sapiens	20-23
19457109-13	2009	Our data suggest a potential sequence of events triggered by the neurotoxic product of inflammation PGJ2 leading to tau pathology.	9-deoxy-delta-9-prostaglandin D2	100-104	microtubule associated protein tau	Homo sapiens	116-119
19457109-15	2009	If cells fail to overcome the toxic effects induced by PGJ2, including accumulation of Ub proteins, apoptosis kicks in triggering caspase activation and tau cleavage, the clearance of which by cathepsins could be compromised culminating in tau pathology.	9-deoxy-delta-9-prostaglandin D2	55-59	microtubule associated protein tau	Homo sapiens	153-156
19457109-15	2009	If cells fail to overcome the toxic effects induced by PGJ2, including accumulation of Ub proteins, apoptosis kicks in triggering caspase activation and tau cleavage, the clearance of which by cathepsins could be compromised culminating in tau pathology.	9-deoxy-delta-9-prostaglandin D2	55-59	microtubule associated protein tau	Homo sapiens	240-243
19211687-11	2009	Moreover, SP600125 or SN50 effectively blocked SGLT expression and alpha-MG uptake in BSA- or PPARgamma agonists (troglitazone or PGJ2)-treated PTCs.	9-deoxy-delta-9-prostaglandin D2	130-134	peroxisome proliferator activated receptor gamma	Homo sapiens	94-103
20354189-8	2010	Mutation of the IRE sequence, or downregulation of IRP1 expression, blocks the effect of PGJ(2) on HIF2a translation.	9-deoxy-delta-9-prostaglandin D2	89-95	aconitase 1	Homo sapiens	51-55
20354189-8	2010	Mutation of the IRE sequence, or downregulation of IRP1 expression, blocks the effect of PGJ(2) on HIF2a translation.	9-deoxy-delta-9-prostaglandin D2	89-95	endothelial PAS domain protein 1	Homo sapiens	99-104
19240648-2	2009	Both prostaglandin D2 (PGD2) and its dehydration end product 15-deoxy-Delta-prostaglandin J2 (15d-PGJ2) seem to play important roles in regulating inflammation, via both receptor-dependent (DP1 and DP2 receptors) and receptor-independent mechanisms.	9-deoxy-delta-9-prostaglandin D2	97-102	prostaglandin D2 synthase	Homo sapiens	5-21
19240648-2	2009	Both prostaglandin D2 (PGD2) and its dehydration end product 15-deoxy-Delta-prostaglandin J2 (15d-PGJ2) seem to play important roles in regulating inflammation, via both receptor-dependent (DP1 and DP2 receptors) and receptor-independent mechanisms.	9-deoxy-delta-9-prostaglandin D2	97-102	prostaglandin D2 receptor	Homo sapiens	190-225
19136476-7	2009	Treatment with the HO-1 inhibitor ZnPP abolished the migrative phenotype of 15d-PGJ2-treated MCF-7 cells.	9-deoxy-delta-9-prostaglandin D2	80-84	heme oxygenase 1	Homo sapiens	19-23
19262292-6	2009	The lung maturation effect of PPARgamma agonists was also confirmed by another PPARgamma agonist, the naturally occurring PPARgamma ligand prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	139-155	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	79-88
19262292-6	2009	The lung maturation effect of PPARgamma agonists was also confirmed by another PPARgamma agonist, the naturally occurring PPARgamma ligand prostaglandin J2.	9-deoxy-delta-9-prostaglandin D2	139-155	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	79-88
19111547-5	2009	Quantification of clock gene mRNAs following PGJ(2) administration additionally revealed a rapid decrease in the Per1, Rev-erbAalpha and Dbp levels.	9-deoxy-delta-9-prostaglandin D2	45-51	nuclear receptor subfamily 1 group D member 1	Homo sapiens	119-132
19111547-5	2009	Quantification of clock gene mRNAs following PGJ(2) administration additionally revealed a rapid decrease in the Per1, Rev-erbAalpha and Dbp levels.	9-deoxy-delta-9-prostaglandin D2	45-51	D-box binding PAR bZIP transcription factor	Homo sapiens	137-140
18983509-0	2009	15-deoxy-Delta12,14 prostaglandin J2-induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis.	9-deoxy-delta-9-prostaglandin D2	20-36	heme oxygenase 1	Homo sapiens	45-61
18818877-5	2008	Phosphorylation, half-life, and the nucleo-cytoplasmic traffic of p27 protein were altered by 15d-PGJ2 by mechanisms dependent on PI3K/Akt activity.	9-deoxy-delta-9-prostaglandin D2	98-102	dynactin subunit 6	Homo sapiens	66-69
18818877-5	2008	Phosphorylation, half-life, and the nucleo-cytoplasmic traffic of p27 protein were altered by 15d-PGJ2 by mechanisms dependent on PI3K/Akt activity.	9-deoxy-delta-9-prostaglandin D2	98-102	AKT serine/threonine kinase 1	Homo sapiens	135-138
18755491-0	2008	PGJ2 antagonizes NF-kappaB-induced HIV-1 LTR activation in colonic epithelial cells.	9-deoxy-delta-9-prostaglandin D2	0-4	nuclear factor kappa B subunit 1	Homo sapiens	17-26
18208815-13	2008	In conclusion, Ox-LDL-induced increase in 15d-PGJ(2) level through ERK1/2-dependent COX-2 expression is one of the mechanisms of PPARalpha and PPARgamma activation in macrophages.	9-deoxy-delta-9-prostaglandin D2	45-52	mitogen-activated protein kinase 3	Mus musculus	67-73
18161004-7	2008	High concentrations (10-100 microM/L 15-d Delta PGJ2 and pioglitazone) of PPAR-gamma ligand suppressed growth, while low concentrations (0.01-1 microM/L 15-d Delta PGJ2 and pioglitazone) of PPAR-gamma ligand promoted growth.	9-deoxy-delta-9-prostaglandin D2	48-52	peroxisome proliferator activated receptor gamma	Homo sapiens	74-84
18081944-8	2008	However, a major stimulation of Angptl4/FIAF expression was observed with rosiglitazone and the inflammatory prostaglandins PGD2 and PGJ2.	9-deoxy-delta-9-prostaglandin D2	133-137	angiopoietin-like 4	Mus musculus	32-39
18081944-8	2008	However, a major stimulation of Angptl4/FIAF expression was observed with rosiglitazone and the inflammatory prostaglandins PGD2 and PGJ2.	9-deoxy-delta-9-prostaglandin D2	133-137	angiopoietin-like 4	Mus musculus	40-44
18208815-13	2008	In conclusion, Ox-LDL-induced increase in 15d-PGJ(2) level through ERK1/2-dependent COX-2 expression is one of the mechanisms of PPARalpha and PPARgamma activation in macrophages.	9-deoxy-delta-9-prostaglandin D2	45-52	prostaglandin-endoperoxide synthase 2	Mus musculus	84-89
18208815-13	2008	In conclusion, Ox-LDL-induced increase in 15d-PGJ(2) level through ERK1/2-dependent COX-2 expression is one of the mechanisms of PPARalpha and PPARgamma activation in macrophages.	9-deoxy-delta-9-prostaglandin D2	45-52	peroxisome proliferator activated receptor alpha	Mus musculus	129-138
18208815-13	2008	In conclusion, Ox-LDL-induced increase in 15d-PGJ(2) level through ERK1/2-dependent COX-2 expression is one of the mechanisms of PPARalpha and PPARgamma activation in macrophages.	9-deoxy-delta-9-prostaglandin D2	45-52	peroxisome proliferator activated receptor gamma	Mus musculus	143-152
18278065-5	2008	KEY RESULTS: In growth-arrested cardiac fibroblasts, PPAR-gamma ligands rosiglitazone and 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) dose-dependently attenuated Ang II-induced cell proliferation and expression of PAI-1, collagen type-I, collagen type-III and fibronectin.	9-deoxy-delta-9-prostaglandin D2	112-128	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	53-63
18047631-3	2008	The aim of the present study was to test whether PPAR-gamma agonists 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ2) and pioglitazone could alter AngII-induced collagen type I formation in vascular adventitial fibroblasts via reactive oxygen species (ROS).	9-deoxy-delta-9-prostaglandin D2	114-119	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	49-59
18047631-3	2008	The aim of the present study was to test whether PPAR-gamma agonists 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ2) and pioglitazone could alter AngII-induced collagen type I formation in vascular adventitial fibroblasts via reactive oxygen species (ROS).	9-deoxy-delta-9-prostaglandin D2	114-119	angiotensinogen	Rattus norvegicus	150-155
17169324-3	2007	Here we show that the cyPG 15-deoxy-Delta(12,14)-PGJ2 (15d-PGJ2) binds to GSTP1-1 covalently, as demonstrated by mass spectrometry and by the use of biotinylated 15d-PGJ2.	9-deoxy-delta-9-prostaglandin D2	49-53	glutathione S-transferase pi 1	Homo sapiens	74-81
17981670-5	2008	While 15d-prostaglandin J2 (15d PGJ2) is the natural ligand of PPAR-gamma, the thiazolidinediones (TZDs) are potent exogenous agonists.	9-deoxy-delta-9-prostaglandin D2	32-36	peroxisome proliferator activated receptor gamma	Homo sapiens	63-73
17982241-5	2007	The 15d-PGJ2-induced dedifferentiation effect seems to be dependent on PPAR-gamma activation, as the PPRE luciferase activity increased and PPAR-gamma antagonist, BADGE, abolished type II collagen expression.	9-deoxy-delta-9-prostaglandin D2	8-12	peroxisome proliferator activated receptor gamma	Homo sapiens	71-81
17982241-5	2007	The 15d-PGJ2-induced dedifferentiation effect seems to be dependent on PPAR-gamma activation, as the PPRE luciferase activity increased and PPAR-gamma antagonist, BADGE, abolished type II collagen expression.	9-deoxy-delta-9-prostaglandin D2	8-12	peroxisome proliferator activated receptor gamma	Homo sapiens	140-150
17551094-0	2007	A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production.	9-deoxy-delta-9-prostaglandin D2	225-241	TNF superfamily member 10	Homo sapiens	131-186
17551094-0	2007	A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production.	9-deoxy-delta-9-prostaglandin D2	225-241	TNF superfamily member 10	Homo sapiens	188-193
17407572-12	2007	Secondly, estrogen may antagonize PPARgamma signaling, thought to inhibit fibroid growth and survival, at two points in the PPAR pathway: 1) through increased ANXA1 gene expression which can inhibit phospholipase A2 activity and in turn decrease arachidonic acid synthesis, and 2) by decreasing L-PGDS expression which would reduce synthesis of PGJ2, an endogenous ligand for PPARgamma.	9-deoxy-delta-9-prostaglandin D2	345-349	peroxisome proliferator activated receptor gamma	Homo sapiens	34-43
17407572-12	2007	Secondly, estrogen may antagonize PPARgamma signaling, thought to inhibit fibroid growth and survival, at two points in the PPAR pathway: 1) through increased ANXA1 gene expression which can inhibit phospholipase A2 activity and in turn decrease arachidonic acid synthesis, and 2) by decreasing L-PGDS expression which would reduce synthesis of PGJ2, an endogenous ligand for PPARgamma.	9-deoxy-delta-9-prostaglandin D2	345-349	peroxisome proliferator activated receptor alpha	Homo sapiens	34-38
17407572-12	2007	Secondly, estrogen may antagonize PPARgamma signaling, thought to inhibit fibroid growth and survival, at two points in the PPAR pathway: 1) through increased ANXA1 gene expression which can inhibit phospholipase A2 activity and in turn decrease arachidonic acid synthesis, and 2) by decreasing L-PGDS expression which would reduce synthesis of PGJ2, an endogenous ligand for PPARgamma.	9-deoxy-delta-9-prostaglandin D2	345-349	annexin A1	Homo sapiens	159-164
17148750-9	2007	These findings suggest that, whereas PGJ(2)-induced UPR activation is associated with an inhibition of cytokine signaling, prolonged UPR activation results in cell death, and that eIF2alpha phosphorylation may function in a protective manner to attenuate cell death.	9-deoxy-delta-9-prostaglandin D2	37-43	eukaryotic translation initiation factor 2A	Rattus norvegicus	180-189
17489560-6	2007	Whereas 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and Delta12-PGJ2 preferentially target the C-terminal region containing cysteines 181 and 184, PGA1 and 8-iso-PGA1 bind mainly to cysteine 118, located in the GTP-binding motif.	9-deoxy-delta-9-prostaglandin D2	50-54	autoimmune regulator	Homo sapiens	166-170
17151289-7	2007	Kupffer cell depletion by pretreating with gadolinium chloride 1) attenuated increased mRNA expression of HO-1 in kidney; 2) attenuated the increase in TNFalpha; 3) inhibited the increase in Nrf2 nuclear translocation; and 4) tended to attenuate renal 15-d-PGJ2 levels.	9-deoxy-delta-9-prostaglandin D2	257-261	nuclear factor, erythroid derived 2, like 2	Mus musculus	191-195
17161435-5	2007	On the other hand, the SLIM1 expression induced by the 25-HC or 9-cis RA (as well as SM alpha-actin and CNN-1) was decreased by the treatment of 15d-PGJ2.	9-deoxy-delta-9-prostaglandin D2	149-153	four and a half LIM domains 1	Rattus norvegicus	23-28
17161435-5	2007	On the other hand, the SLIM1 expression induced by the 25-HC or 9-cis RA (as well as SM alpha-actin and CNN-1) was decreased by the treatment of 15d-PGJ2.	9-deoxy-delta-9-prostaglandin D2	149-153	calponin 1	Rattus norvegicus	104-109
16844232-4	2006	In this study, we show that the PPARgamma antagonists, Bisphenol A diglycidyl ether (BADGE) and 2-chloro-5-nitro-N-(4-pyridyl)benzamide (T0070907), reverse the inhibition of EAE by the PPARgamma agonists, Ciglitazone and 15-Deoxy-Delta(12,14)-Prostaglandin J2, in C57BL/6 wild-type and PPARgamma+/- mice.	9-deoxy-delta-9-prostaglandin D2	243-259	peroxisome proliferator activated receptor gamma	Mus musculus	32-41
16842938-2	2006	Prostanoids have been proposed as potent adipogenic hormones, e.g. metabolites of prostaglandin J2 (PGJ2) bind and activate PPARgamma.	9-deoxy-delta-9-prostaglandin D2	82-98	peroxisome proliferator activated receptor gamma	Homo sapiens	124-133
16842938-2	2006	Prostanoids have been proposed as potent adipogenic hormones, e.g. metabolites of prostaglandin J2 (PGJ2) bind and activate PPARgamma.	9-deoxy-delta-9-prostaglandin D2	100-104	peroxisome proliferator activated receptor gamma	Homo sapiens	124-133
16939878-6	2006	Moreover, the inhibitory effect of 15 PGJ2 was not abrogated by co-incubation with PPARgamma antagonists and did not involve the modulation of STAT-1, AKT or ERK1/2 phosphorylation, nor CIITA, IRF1 or IRF2 transcription.	9-deoxy-delta-9-prostaglandin D2	38-42	interferon regulatory factor 2	Homo sapiens	201-205
16939878-7	2006	In conclusion, 15 PGJ2 inhibits strongly and specifically the IFNgamma-induced MHC class II expression on RPE cells by a PPARgamma independent mechanism.	9-deoxy-delta-9-prostaglandin D2	18-22	interferon gamma	Homo sapiens	62-70
16406650-0	2006	Prostaglandin J2 reduces catechol-O-methyltransferase activity and enhances dopamine toxicity in neuronal cells.	9-deoxy-delta-9-prostaglandin D2	0-16	catechol-O-methyltransferase	Homo sapiens	25-53
16939878-7	2006	In conclusion, 15 PGJ2 inhibits strongly and specifically the IFNgamma-induced MHC class II expression on RPE cells by a PPARgamma independent mechanism.	9-deoxy-delta-9-prostaglandin D2	18-22	peroxisome proliferator activated receptor gamma	Homo sapiens	121-130
16794398-8	2006	Plasma 15-deoxy-Delta12, 14-prostaglandin J2 (PGJ2, an endogenous PPAR-gamma agonist) levels were also increased in androstenediol-treated T-H rats, but these levels were lower than those observed in shams.	9-deoxy-delta-9-prostaglandin D2	46-50	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	66-76
16939878-2	2006	In the present work, we investigated the effects of 15-deoxy-12,14-prostaglandin J2 (15 PGJ2), an endogenous ligand of PPARgamma, on the IFNgamma-induced expression of MHC class II on RPE cells.	9-deoxy-delta-9-prostaglandin D2	88-92	peroxisome proliferator activated receptor gamma	Homo sapiens	119-128
16939878-2	2006	In the present work, we investigated the effects of 15-deoxy-12,14-prostaglandin J2 (15 PGJ2), an endogenous ligand of PPARgamma, on the IFNgamma-induced expression of MHC class II on RPE cells.	9-deoxy-delta-9-prostaglandin D2	88-92	interferon gamma	Homo sapiens	137-145
16939878-4	2006	We demonstrated that 15 PGJ2 inhibited the IFNgamma-mediated induction of MHC class II on RPE cells without affecting the level of MHC class I and CD54 expression.	9-deoxy-delta-9-prostaglandin D2	24-28	interferon gamma	Homo sapiens	43-51
16939878-6	2006	Moreover, the inhibitory effect of 15 PGJ2 was not abrogated by co-incubation with PPARgamma antagonists and did not involve the modulation of STAT-1, AKT or ERK1/2 phosphorylation, nor CIITA, IRF1 or IRF2 transcription.	9-deoxy-delta-9-prostaglandin D2	38-42	class II major histocompatibility complex transactivator	Homo sapiens	186-191
16939878-6	2006	Moreover, the inhibitory effect of 15 PGJ2 was not abrogated by co-incubation with PPARgamma antagonists and did not involve the modulation of STAT-1, AKT or ERK1/2 phosphorylation, nor CIITA, IRF1 or IRF2 transcription.	9-deoxy-delta-9-prostaglandin D2	38-42	interferon regulatory factor 1	Homo sapiens	193-197
16406650-4	2006	Herein, we characterize the effects of a neurotoxic product of inflammation, prostaglandin J2 (PGJ2), on catechol-O-methyltransferase (COMT) in human dopaminergic-like neuroblastoma SK-N-SH cells and rat (P2) cortical neurons.	9-deoxy-delta-9-prostaglandin D2	77-93	catechol-O-methyltransferase	Homo sapiens	105-133
16406650-4	2006	Herein, we characterize the effects of a neurotoxic product of inflammation, prostaglandin J2 (PGJ2), on catechol-O-methyltransferase (COMT) in human dopaminergic-like neuroblastoma SK-N-SH cells and rat (P2) cortical neurons.	9-deoxy-delta-9-prostaglandin D2	77-93	catechol-O-methyltransferase	Homo sapiens	135-139
16406650-4	2006	Herein, we characterize the effects of a neurotoxic product of inflammation, prostaglandin J2 (PGJ2), on catechol-O-methyltransferase (COMT) in human dopaminergic-like neuroblastoma SK-N-SH cells and rat (P2) cortical neurons.	9-deoxy-delta-9-prostaglandin D2	95-99	catechol-O-methyltransferase	Homo sapiens	105-133
16406650-4	2006	Herein, we characterize the effects of a neurotoxic product of inflammation, prostaglandin J2 (PGJ2), on catechol-O-methyltransferase (COMT) in human dopaminergic-like neuroblastoma SK-N-SH cells and rat (P2) cortical neurons.	9-deoxy-delta-9-prostaglandin D2	95-99	catechol-O-methyltransferase	Homo sapiens	135-139
16406650-6	2006	PGJ2 treatment reduced the expression and activity of COMT, induced its sequestration into perinuclear aggregates and potentiated dopamine toxicity.	9-deoxy-delta-9-prostaglandin D2	0-4	catechol-O-methyltransferase	Homo sapiens	54-58
16406650-8	2006	Our results indicate that COMT impairment induced by PGJ2 treatment may increase the concentration of dopamine (or its metabolites) to neurotoxic levels.	9-deoxy-delta-9-prostaglandin D2	53-57	catechol-O-methyltransferase	Homo sapiens	26-30
16484546-5	2006	Recently, we examined the role of PPARgamma in EAE and observed that administration of the PPARgamma agonist 15-deoxy-Delta(12,14) prostaglandin J2 exerted a significant therapeutic effect predominantly by inhibiting the activation and expansion of encephalitogenic T cells.	9-deoxy-delta-9-prostaglandin D2	131-147	peroxisome proliferator activated receptor gamma	Homo sapiens	34-43
16499711-13	2006	The coordinated synthesis of Delta(12)PGJ(2), a natural ligand for PPARgamma-1, with the increased expression of PPARgamma-1, suggests that biomechanical transduction pathways that initially involve the activation of cyclooxygenases may also involve the activation of the Delta(12)PGJ(2)-PPAR pathway.	9-deoxy-delta-9-prostaglandin D2	38-44	peroxisome proliferator activated receptor alpha	Homo sapiens	67-71
16484546-5	2006	Recently, we examined the role of PPARgamma in EAE and observed that administration of the PPARgamma agonist 15-deoxy-Delta(12,14) prostaglandin J2 exerted a significant therapeutic effect predominantly by inhibiting the activation and expansion of encephalitogenic T cells.	9-deoxy-delta-9-prostaglandin D2	131-147	peroxisome proliferator activated receptor gamma	Homo sapiens	91-100
16236024-1	2006	PPARgamma (peroxisome proliferator-activated receptor gamma) is a nuclear receptor that is activated by natural lipid metabolites, including 15d-PGJ2 (15-deoxy-Delta(12,14)-prostaglandin J2).	9-deoxy-delta-9-prostaglandin D2	173-189	peroxisome proliferator activated receptor gamma	Homo sapiens	0-9
16236024-1	2006	PPARgamma (peroxisome proliferator-activated receptor gamma) is a nuclear receptor that is activated by natural lipid metabolites, including 15d-PGJ2 (15-deoxy-Delta(12,14)-prostaglandin J2).	9-deoxy-delta-9-prostaglandin D2	173-189	peroxisome proliferator activated receptor gamma	Homo sapiens	11-59
16337105-6	2006	Moreover, 15-d PGJ2 down-regulation of the expression of transforming growth factor beta(1) and connective tissue growth factor which had been induced by BLM.	9-deoxy-delta-9-prostaglandin D2	15-19	transforming growth factor, beta 1	Mus musculus	57-91
16156795-5	2005	15d-PGJ2 suppression of Prm3 transcriptional activity and TPbeta mRNA expression was found to occur through a novel mechanism involving direct binding of PPARgamma-retinoic acid X receptor (RXR) heterodimers to a PPARgamma response element (PPRE) composed of two imperfect hexameric direct repeat (DR) sequences centred at -159 and -148, respectively, spaced by five nucleotides (DR5).	9-deoxy-delta-9-prostaglandin D2	4-8	protamine 3	Homo sapiens	24-28
16156795-5	2005	15d-PGJ2 suppression of Prm3 transcriptional activity and TPbeta mRNA expression was found to occur through a novel mechanism involving direct binding of PPARgamma-retinoic acid X receptor (RXR) heterodimers to a PPARgamma response element (PPRE) composed of two imperfect hexameric direct repeat (DR) sequences centred at -159 and -148, respectively, spaced by five nucleotides (DR5).	9-deoxy-delta-9-prostaglandin D2	4-8	hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta	Homo sapiens	58-64
16156795-5	2005	15d-PGJ2 suppression of Prm3 transcriptional activity and TPbeta mRNA expression was found to occur through a novel mechanism involving direct binding of PPARgamma-retinoic acid X receptor (RXR) heterodimers to a PPARgamma response element (PPRE) composed of two imperfect hexameric direct repeat (DR) sequences centred at -159 and -148, respectively, spaced by five nucleotides (DR5).	9-deoxy-delta-9-prostaglandin D2	4-8	retinoid X receptor alpha	Homo sapiens	154-188
16156795-5	2005	15d-PGJ2 suppression of Prm3 transcriptional activity and TPbeta mRNA expression was found to occur through a novel mechanism involving direct binding of PPARgamma-retinoic acid X receptor (RXR) heterodimers to a PPARgamma response element (PPRE) composed of two imperfect hexameric direct repeat (DR) sequences centred at -159 and -148, respectively, spaced by five nucleotides (DR5).	9-deoxy-delta-9-prostaglandin D2	4-8	retinoid X receptor alpha	Homo sapiens	190-193
16156795-5	2005	15d-PGJ2 suppression of Prm3 transcriptional activity and TPbeta mRNA expression was found to occur through a novel mechanism involving direct binding of PPARgamma-retinoic acid X receptor (RXR) heterodimers to a PPARgamma response element (PPRE) composed of two imperfect hexameric direct repeat (DR) sequences centred at -159 and -148, respectively, spaced by five nucleotides (DR5).	9-deoxy-delta-9-prostaglandin D2	4-8	peroxisome proliferator activated receptor gamma	Homo sapiens	154-163
16253239-5	2005	15-Deoxy-Delta(12,14) prostaglandin J2 is, an endogenous ligand for peroxisome proliferator-activated receptor gamma (PPARgamma), has been known to possess proapoptotic potential in diverse cell types.	9-deoxy-delta-9-prostaglandin D2	22-38	peroxisome proliferator activated receptor gamma	Homo sapiens	68-116
16253239-5	2005	15-Deoxy-Delta(12,14) prostaglandin J2 is, an endogenous ligand for peroxisome proliferator-activated receptor gamma (PPARgamma), has been known to possess proapoptotic potential in diverse cell types.	9-deoxy-delta-9-prostaglandin D2	22-38	peroxisome proliferator activated receptor gamma	Homo sapiens	118-127
16077033-0	2005	15-deoxy-Delta12,14 prostaglandin J2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor gamma by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells.	9-deoxy-delta-9-prostaglandin D2	20-36	Kruppel like factor 4	Homo sapiens	50-71
16077033-0	2005	15-deoxy-Delta12,14 prostaglandin J2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor gamma by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells.	9-deoxy-delta-9-prostaglandin D2	20-36	mitogen-activated protein kinase 1	Homo sapiens	207-244
16077033-1	2005	15-Deoxy-Delta(12,14) prostaglandin J2 (15d-PGJ2) is a natural ligand for the peroxisome proliferator-activated receptor gamma (PPARgamma) that exhibits antiproliferative activity in colon cancer cells, but its mechanism of action is still poorly understood.	9-deoxy-delta-9-prostaglandin D2	22-38	peroxisome proliferator activated receptor gamma	Homo sapiens	78-126
16077033-1	2005	15-Deoxy-Delta(12,14) prostaglandin J2 (15d-PGJ2) is a natural ligand for the peroxisome proliferator-activated receptor gamma (PPARgamma) that exhibits antiproliferative activity in colon cancer cells, but its mechanism of action is still poorly understood.	9-deoxy-delta-9-prostaglandin D2	22-38	peroxisome proliferator activated receptor gamma	Homo sapiens	128-137
16020752-1	2005	OBJECTIVE: We recently reported that the peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) and ciglitazone increased cultured endothelial cell nitric oxide (NO) release without increasing the expression of endothelial nitric oxide synthase (eNOS).	9-deoxy-delta-9-prostaglandin D2	132-148	peroxisome proliferator activated receptor gamma	Homo sapiens	41-89
16020752-1	2005	OBJECTIVE: We recently reported that the peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) and ciglitazone increased cultured endothelial cell nitric oxide (NO) release without increasing the expression of endothelial nitric oxide synthase (eNOS).	9-deoxy-delta-9-prostaglandin D2	132-148	peroxisome proliferator activated receptor gamma	Homo sapiens	91-100
16020752-1	2005	OBJECTIVE: We recently reported that the peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) and ciglitazone increased cultured endothelial cell nitric oxide (NO) release without increasing the expression of endothelial nitric oxide synthase (eNOS).	9-deoxy-delta-9-prostaglandin D2	132-148	nitric oxide synthase 3	Homo sapiens	275-308
16020752-1	2005	OBJECTIVE: We recently reported that the peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) and ciglitazone increased cultured endothelial cell nitric oxide (NO) release without increasing the expression of endothelial nitric oxide synthase (eNOS).	9-deoxy-delta-9-prostaglandin D2	154-158	peroxisome proliferator activated receptor gamma	Homo sapiens	41-89
16020752-1	2005	OBJECTIVE: We recently reported that the peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) and ciglitazone increased cultured endothelial cell nitric oxide (NO) release without increasing the expression of endothelial nitric oxide synthase (eNOS).	9-deoxy-delta-9-prostaglandin D2	154-158	peroxisome proliferator activated receptor gamma	Homo sapiens	91-100
16020752-1	2005	OBJECTIVE: We recently reported that the peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) and ciglitazone increased cultured endothelial cell nitric oxide (NO) release without increasing the expression of endothelial nitric oxide synthase (eNOS).	9-deoxy-delta-9-prostaglandin D2	154-158	nitric oxide synthase 3	Homo sapiens	275-308